Role Of Hyperglycemia and Aldosterone on Renal ACE2 aND Albuminuria in db/db Mice by Chodavarapu, Harshita
Wright State University 
CORE Scholar 
Browse all Theses and Dissertations Theses and Dissertations 
2011 
Role Of Hyperglycemia and Aldosterone on Renal ACE2 aND 
Albuminuria in db/db Mice 
Harshita Chodavarapu 
Wright State University 
Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all 
 Part of the Pharmacology, Toxicology and Environmental Health Commons 
Repository Citation 
Chodavarapu, Harshita, "Role Of Hyperglycemia and Aldosterone on Renal ACE2 aND Albuminuria in db/
db Mice" (2011). Browse all Theses and Dissertations. 500. 
https://corescholar.libraries.wright.edu/etd_all/500 
This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has 
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE 
Scholar. For more information, please contact library-corescholar@wright.edu. 
 
 
 
 
ROLE OF HYPERGLYCEMIA AND 
ALDOSTERONE ON RENAL ACE2 AND 
ALBUMINURIA IN db/db MICE 
 
A thesis submitted in partial fulfillment  
of the requirements for the degree of  
Master of Science  
 
By 
 
HARSHITA CHODAVARAPU   
B. Pharm, St. Peter’s Institute of Pharmaceutical Sciences, Andhra Pradesh, India 2009 
 
 
 
 
 
 
2011 
Wright State University 
 
 
 
 
 
ii 
 
WRIGHT STATE UNIVERSITY 
SCHOOL OF GRADUATE STUDIES 
 
                                                               Date: September 6, 2011 
 
 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION 
BY Harshita Chodavarapu ENTITLED “Role Of Hyperglycemia And Aldosterone On Renal 
ACE2 And Albuminuria In db/db Mice” BE ACCEPTED IN PARTIAL FULFILLMENT OF 
THE REQUIREMENTS FOR THE DEGREE OF Master Of Science.  
 
 
 
Khalid M.Elased, R.Ph., Ph.D. 
Thesis Director 
                                  
 
Mariana Morris, Ph.D., Chair 
                                                                      Department of Pharmacology and Toxicology 
 
 
  
Committee on Final Examination 
 
 
Khalid M. Elased, R.Ph., Ph.D. 
 
Mariana Morris, Ph.D. 
 
 
Mauricio DiFulvio, Ph.D. 
 
Andrew T. Hsu, Ph.D. 
Dean, School of Graduate Studies 
 
iii 
 
ABSTRACT 
Chodavarapu, Harshita. M.S., Department of Pharmacology and Toxicology, Wright State 
University, 2011. Role of Hyperglycemia and Aldosterone on Renal ACE2 and Albuminuria in 
db/db Mice. 
 
          Diabetic nephropathy (DN) is one of the microvascular complications of type II diabetes 
and a leading cause for the development of end stage renal disease. Renin angiotensin system 
(RAS) plays a pivotal role in the development and progression of diabetic nephropathy. 
Hyperglycemia activates RAS and increases tissue and circulating levels of angiotensin II (Ang 
II) and aldosterone. A new component of RAS, angiotensin converting enzyme 2 (ACE2), has 
been shown to be renoprotective in early stages of diabetes. The aim of this study is to test the 
hypothesis that strict glycemic control using rosiglitazone or treatment with mineralocorticoid 
receptor (MR) antagonist, spironolactone would impart renoprotection in db/db mice via 
upregulation of renal ACE2. Lean control and db/db mice were fed either rosiglitazone or 
spironolactone for 10 weeks. Diabetic db/db mice demonstrated hyperglycemia and early onset 
of microalbuminuria compared to lean control mice. Moreover, elevation in plasma aldosterone 
levels of db/db mice supports the role of aldosterone in mediating renal injury. Western blot 
analysis revealed an increase in renal and urinary ACE2 expression of db/db mice. In addition, 
there was a significant increase in renal and urinary ACE2 activity in db/db mice compared to 
lean controls. Further, renal mineralocorticoid receptor (MR) and neprilysin (NEP) protein 
expression increased and decreased respectively in db/db mice compared to controls. 
Immunohistochemistry demonstrated decreased renal NEP protein expression in db/db mice 
compared to controls. Periodic acid Schiff stained renal sections of db/db mice showed 
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glomerular basement membrane thickening and mild mesangial expansion than that of lean 
control mice. 
Chronic rosiglitazone treatment normalized the blood glucose levels and improved glucose 
tolerance in db/db mice but did not alter the increased plasma aldosterone levels. In contrast, 
chronic treatment with spironolactone significantly increased plasma aldosterone levels in lean 
control and db/db mice without altering blood glucose levels. Urinary albumin excretion rate 
decreased significantly in rosiglitazone and spironolactone treated db/db mice. However, both 
rosiglitazone and spironolactone decreased renal ACE2 protein expression and enzyme activity 
in db/db mice. In addition, urinary ACE2 excretion and enzyme activity were also decreased 
after treatment with rosiglitazone. Although spironolactone showed no effect on renal MR 
expression, rosiglitazone significantly decreased the renal MR expression in db/db mice. In 
addition, rosiglitazone treatment significantly increased renal NEP protein expression in db/db 
mice. 
In conclusion, rosiglitazone and spironolactone attenuate albuminuria and impart renal protection 
independent of ACE2. Upregulation of renal NEP suggests the involvement of alternative Ang 
(1-7) forming enzyme apart from ACE2 in the renoprotection mediated by rosiglitazone. These 
findings provide new insights for the possible role of NEP in diabetic renal injury. 
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1. INTRODUCTION 
Diabetes 
 Diabetes mellitus is a metabolic disorder resulting in disturbances of carbohydrate, fat and 
protein metabolisms caused by a relative or complete lack of insulin or a defect in the normal 
actions of insulin. According to the International Diabetes Federation, approximately 194 million 
people were suffering from type II diabetes in 2003 (Matheson et al., 2010). This worldwide 
epidemic is estimated to reach 366 million people by 2030 (Hayashi et al., 2010). In the United 
States alone, 25.8 million people are suffering from diabetes (Zhang, 2011). The economic cost 
of diabetes is estimated to reach $490 billion by 2030 (Farag & Gaballa, 2011). Type II diabetes 
is considered to be the most common form of diabetes and accounts for 90-95% of the people 
with the disease (Ettaro et al., 2004). There are several risk factors such as family history, 
obesity, hypertension and dyslipidemia contributing to the development of type II diabetes 
(Bindom & Lazartigues, 2009). Type II diabetes leads to the development of many long-term 
macrovascular and microvascular complications. Macrovascular complications include 
cardiovascular and cerebrovascular diseases whereas microvascular include nephropathy, 
retinopathy and neuropathy (Massi-Benedetti, 2002). Diabetic subjects are more prone to the risk 
of development of heart disease and stroke compared to non-diabetic subjects (Haffner et al., 
1998).  
Diabetes mellitus can be classified into three types. Type I diabetes, also known as insulin 
dependent diabetes mellitus (IDDM) or juvenile onset diabetes, is a chronic metabolic disorder 
caused by β-cell destruction that leads to insulin deficiency. It requires insulin treatment 
constantly. Type II diabetes is characterized by relative resistance to insulin and dysfunction of 
2 
 
the β-cells in the pancreatic islets of Langerhans. The third type, gestational diabetes mellitus, 
occurs during pregnancy (Massi-Benedetti, 2002).  
Renin angiotensin system and diabetes  
Renin angiotensin system (RAS) is activated in diabetic human subjects as well as experimental 
animals. An increase in extracellular glucose stimulates angiotensinogen gene expression in rat 
proximal tubules by generating reactive oxygen species (Hsieh et al., 2002). The glucose 
response element present on the angiotensinogen gene promoter region of tubular cells is also 
responsible for the increased angiotensinogen gene and angiotensin II (Ang II) secretion induced 
by high glucose concentration (Zhang et al., 2002). Ang II and angiotensin converting enzyme 
(ACE) are involved in the initiation and progression of several diabetic complications such as 
retinopathy, nephropathy, hypertension and cardiovascular disease (Ribeiro-Oliveira, Jr. et al., 
2008). Clinical trials showed that the blockade of RAS with angiotensin converting enzyme 
inhibitors (ACEIs) and angiotensin type 1 receptor blockers (ARBs) decreases the cases of 
diabetes mellitus (Filipiak, 2010). Ang II is responsible for the development of endothelial cell 
dysfunction, insulin resistance, inflammation and several proliferative effects (Watanabe et al., 
2005). Augmentation of renal Ang II levels leads to the development of diabetic nephropathy 
which progresses into end stage renal disease (Giacchetti et al., 2005). ACEIs or ARBs increase 
renal plasma flow and glomerular filtration rate in type I diabetic patients (Hollenberg et al., 
2003). Blockade of the Ang II type 1 receptor (AT1R) augmented renal plasma flow and 
suppressed filtration fraction in the type II diabetic patients suggesting that a RAS blockade 
improves intrarenal hemodynamics (Fliser et al., 2005). Many studies have shown that Ang II via 
the AT1R signaling pathway induces insulin resistance which can be reversed by a RAS 
blockade (Velloso et al., 2006; Furuhashi et al., 2004).  
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Renin-Angiotensin System (RAS) enzyme cascade 
 
Modified from (George et al., 2010) 
Renin angiotensin system (RAS) 
The renin angiotensin system plays a crucial role in blood pressure regulation and electrolyte 
balance (de et al., 2000). RAS is not only found in circulation but also expressed in tissues like 
brain, kidney, pancreas, adipocytes and other organs (Campbell, 1987; Campbell, 1987; Leung & 
Chappell, 2003; Campbell, 1987; Kershaw & Flier, 2004). The RAS cascade consists of many 
enzymatic reactions and begins with the formation of angiotensin I (Ang I) from hepatic protein 
angiotensinogen (AGT) via renin (Peach, 1977). Ang I is further converted by ACE, a peptidyl 
dipeptidase that belongs to gluzincin family of metalloproteases, into Ang II (Guy et al., 2003). 
ACE cleaves Ang I at C terminal dipeptide (L-Histidyl-L-Leucine) to generate the 
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vasoconstrictor Ang II which is biologically active (Elased et al., 2006). ACE also cleaves 
bradykinin, vasodilator, at two C-terminal dipeptides and inactivates it (Guy et al., 2003). 
Angiotensin II (Ang II) 
Ang II is an octapeptide which is responsible for the blood volume regulation and vascular 
resistance. Ang II is not only produced in the circulation but also in tissues like brain, kidney, 
heart and blood vessels (de et al., 2000). Studies have shown that there is a dose dependent 
increase in the renal blood flow and glomerular filtration rate upon administration of Ang II 
exogenously (Paul et al., 2006; Yamamoto et al., 2001). Progressive augmentation of intrarenal 
Ang II causes proteinuria and damage to the glomerular filtration barrier (Hoffmann et al., 2004; 
Whaley-Connell et al., 2006). It has been suggested that, in the circulating RAS, plasma Ang II 
production is widely dependent on the generation of renin from the kidney, whereas in the 
vascular tissues, ACE and other peptidases regulate the production of Ang II (Miyazaki & Takai, 
2006).  
Angiotensin II receptors 
 Ang II acts through two major receptor subtypes, AT1R and Ang II type 2 receptor (AT2R) 
(Chen et al., 2003). Two subtypes of the AT1R, AT1A and AT1B have been identified in rats 
(Iwai & Inagami, 1992) and mice (Sasamura et al., 1992). The mouse AT1R genes AT1a and 
AT1b map to different chromosomes: 13 and 3 respectively (MacTaggart et al., 1997). Virtually 
all of the known physiological and pathophysiological actions of Ang II such as regulation of 
arterial blood pressure, electrolyte and water balance, thirst, hormone secretion and renal 
function are mediated through AT1 receptor, in cardiovascular, renal, neuronal, endocrine, 
hepatic and other target cells (de et al., 2000). Smooth muscle contraction, neuronal activation, 
adrenal steroidogenesis and aldosterone secretion, neurosecretion, cell growth and proliferation 
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are considered to be part of the cellular responses induced by AT1R signaling systems (de et al., 
2000). AT1 and AT2 receptors are primarily expressed in blood vessels, heart, kidney, adrenal 
glands and liver of humans (Ribeiro-Oliveira, Jr. et al., 2008). In the kidney AT1 receptors are 
primarily localized in the proximal tubules, thick ascending loop of Henley, glomeruli, arteries 
and juxtaglomerular cells (Tufro-McReddie et al., 1993). Apart from the known beneficial 
physiological functions, AT1 receptors also exhibit some pathological functions such as 
activation of growth factor receptors, reactive oxygen species generation, vasoconstriction and 
other inflammatory responses upon activation by Ang II (Hunyady & Catt, 2006). In contrary, 
AT2 receptors stimulates the formation of bradykinin and nitric oxide, thereby mediating effects 
opposite to the ones of AT1 receptors (Siragy & Carey, 1999).  
Angiotensin (1-7) (Ang 1-7) forming enzymes 
Ang (1-7)  
Ang (1-7), a heptapeptide, is formed from Ang II by the action of ACE2 or from Ang I by the 
action of neutral endopeptidase (NEP) and propyl endopeptidase (PEP) and is further degraded 
to Ang (1-5) by ACE (Donoghue et al., 2000; Tipnis et al., 2000; Chappell et al., 2004; Rice et 
al., 2004). The peptide is not only found in the circulation but also in many tissues like heart, 
kidney, blood vessels, liver and is considered to be a potential target for the development of new 
drug because of its opposing effects on Ang II induced actions (Chappell, 2007; Santos & 
Ferreira, 2007; Simoes e Silva AC et al., 2006). Mas, a G-protein coupled receptor, binds Ang 
(1-7) and modifies the intracellular signaling of AT1R upon activation by Ang II (Bohlen und et 
al., 2000).  
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A study involving transgenic rats overexpressing human ACE2 demonstrated an improvement in 
the endothelial function and decreased Ang II induced vasoconstriction which may be either due 
to the increase in Ang (1-7) or decrease in the oxidative stress caused by Ang II (Rentzsch et al., 
2008). Another study showed that chronic treatment of streptozotocin-treated spontaneously 
hypertensive rats with Ang (1-7) demonstrated an improvement in renal function and endothelial 
function of the renal artery by attenuating NADPH dependent oxidative stress (Benter et al., 
2008). These findings suggest that the ACE2-Ang (1-7)-Mas axis can be considered a potential 
new therapeutic target for cardiovascular and renal protection (Rabelo et al., 2011). 
Angiotensin converting enzyme 2 (ACE2) 
ACE2 was discovered by two independent groups in 2000 and shares 42% homology with the 
catalytic domain of ACE (Tipnis et al., 2000). It is a type I transmembrane glycoprotein 
consisting of 805 amino acids with a molecular weight of 120KDa (Imai et al., 2010). It is 
primarily distributed in heart, kidney (proximal tubular epithelium), testis and endothelial cells 
(Donoghue et al., 2003). It is found to a lesser extent in vascular smooth muscle cells (Burrell et 
al., 2004). ACE2 has also been identified in gastrointestinal tract, brain and lungs (Harmer et al., 
2002). It cleaves a single C-terminal peptide of Ang II to form a vasodilator peptide Ang (1-7) 
(Tipnis et al., 2000; Vickers et al., 2002). It also catalyses the cleavage of single residue from 
Ang I to form Ang (1-9) (Donoghue et al., 2000). Attenuation of ACE2 by SARS-CoV infection 
leads to the development of severe lung failure in SARS suggesting a protective role of ACE2 in 
SARS pathogenesis (Kuba et al., 2005). C-terminal domain of ACE2 has 48% sequence identity 
with a non catalytic protein, collectrin that plays a role in pancreatic beta-cell proliferation and 
insulin exocytosis (Akpinar et al., 2005; Fukui et al., 2005). ACE2 attenuates atherosclerosis and 
counteracts actions of ACE by protecting the endothelial cells from Ang II induced oxidative 
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stress via Ang (1-7) (Lovren et al., 2008). In the rat kidney, ACE2 mRNA is expressed in all 
segments of the nephron except ascending loop of Henley with a higher expression in proximal 
tubules and inner collecting ducts (Li et al., 2005). Moreover, identification of Mas receptor in 
the rat proximal tubular cells indicates that ACE2 might mediate production of Ang (1-7) and 
thus inhibit the effects of locally generated Ang II (Su et al., 2006).  
Neprilysin 
Neprilysin or neutral endopeptidase belongs to the M13 family of zinc-containing 
metallopeptidases and is involved in the metabolism of several biologically active peptides (Rose 
et al., 2002). It degrades Ang I and forms a vasodilator peptide Ang (1-7) (Igic & Behnia, 2007). 
It was first identified in the brush border of proximal tubule and is known to hydrolyze the 
insulin B chain (Kerr & Kenny, 1974). It hydrolyzes many biologically active peptides such as 
tachykinins, bradykinin and natriuretic peptide into their inactive forms (Matsas et al., 1983; 
Gafford et al., 1983; Kenny & Stephenson, 1988; Schwartz et al., 1990). Neprilysin inhibitors are 
also used as therapeutic agents in the field of cardiovascular disease (Bralet & Schwartz, 2001) 
and ACE2 expressed in the podocytes play a role in the formation of vasodilator peptide Ang (1-
7) (Velez et al., 2007). 
Aldosterone 
Aldosterone was the first physiological mineralocorticoid hormone discovered more than 50 
years ago (SIMPSON et al., 1953). Aldosterone is synthesized in the adrenal cortex from its 
precursor deoxycorticosterone and was initially called electrocortin (Funder, 2010). Plasma 
aldosterone levels are regulated by the body fluid volume and plasma Na
+
 and K
+
 levels (Funder, 
2010). Drop in body fluid volume causes angiotensin II to mediate aldosterone secretion 
(Funder, 2010). However drop in [Na
+
] increases the plasma aldosterone levels in 
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angiotensinogen knockout and wild type mice independent of angiotensin II (Funder, 2010; 
Okubo et al., 1997). Studies show that apart from the adrenal cortex, aldosterone can also be 
synthesized locally in other organs like brain, heart, blood vessels and kidney (Kang & Cha, 
2009).  
Aldosterone is also involved in the pathogenesis of cardiovascular, renal and metabolic diseases 
(Takeda, 2009). There is an increase in the aldosterone synthesis during essential hypertension 
(Takeda, 2009). Chronic treatment with ACEIs and/or ARBs in the cardiovascular (CVD) or 
renal diseases is only partially effective due to a mechanism called aldosterone escape 
phenomenon in which aldosterone levels were initially decreased upon treatment with ACEIs 
and/or ARBs but increased with progression of treatment (Sato & Saruta, 2003; Bomback & 
Klemmer, 2007). Incidence of cardiovascular disease is higher in patients with primary 
aldosteronism than in patients with essential hypertension suggesting that aldosterone plays an 
important role in the pathogenesis of cardiovascular and renal disease independent of blood 
pressure (Milliez et al., 2005). As the plasma aldosterone levels rise urinary protein excretion 
rate increases and glomerular filtration rate (GFR) decreases contributing to chronic kidney 
disease (CKD) (Bianchi et al., 2005; Quinkler et al., 2005). According to PAPY study (primary 
aldosteronism prevalence in Italy), essential hypertensive patients with normal plasma 
aldosterone levels have lesser urinary albumin excretion rate compared to those with 
hyperaldosteronism (Rossi et al., 2006). Aldosterone is also known to increase oxidative stress 
by activation of NADPH oxidase enzyme and attenuation of glucose-6-phosphate dehydrogenase 
activity, mechanisms proposed to contribute to kidney injury (Leopold et al., 2007; Grossmann 
& Gekle, 2009).  
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Mineralocorticoid receptors (MR) 
Mineralocorticoid receptors are nuclear steroid receptors which demonstrate genomic effects 
such as regulation of transcription of epithelial sodium channel, serum glucocorticoid- induced 
protein kinase 1(sgk1) and non genomic effects such as extracellular regulated kinase/mitogen-
activated protein kinase pathways (Odermatt & Atanasov, 2009; Grossmann & Gekle, 2009). 
Aldosterone plays a major role in electrolyte and blood pressure regulation and mediates its 
effects through activation of mineralocorticoid receptor (MR) (Nishiyama et al., 2010a). The 
level of glucocorticoids such as cortisol and corticosterone are much higher  in the circulation 
compared to aldosterone (Funder, 2010). Interestingly, glucocorticoids and mineralocorticoids 
have equal affinity for MR compared to aldosterone (Krozowski & Funder, 1983). In order to 
prevent the activation of MR by cortisol in humans or corticosterone in rats, an enzyme called 
11-β hydroxysteroid dehydrogenase converts cortisol to cortisone and corticosterone to 11 
dehydrocorticosterone in rats, enabling the activation of MR by aldosterone only (Edwards et al., 
1988; Funder et al., 1988). However, in vivo studies showed that MRs in some tissues like 
kidney is more sensitive to aldosterone than those located in the heart (Edwards et al., 1988).  
MR blockers 
MR activation by aldosterone and cortisol can be blocked by MR blockers such as eplerenone 
and spironolactone (Tirosh et al., 2010). MR blockers are used in the treatment of hypertension  
as they reduce morbidity and mortality in patients with heart failure (Nishiyama et al., 2010a). 
Antihypertensive effects of MR blockers are mediated through several pathways especially by 
preventing the activation of MR through aldosterone, potassium reabsorption and decrease of 
body fluid levels (Nishiyama et al., 2010a). Combination therapy of MR blockers with ACEIs 
and/or ARBs efficiently reduced proteinuria in a double-blind, randomized, controlled trial 
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carried on CKD patients (Chrysostomou et al., 2006). Spironolactone, a non selective MR 
blocker when coupled with ACEIs decreased albuminuria in patients with diabetic nephropathy 
(Sato et al., 2003). Spironolactone blocks MRs in STZ induced diabetic rats and prevents renal 
fibrosis seen in early diabetic kidney injury (Fujisawa et al., 2004). Some studies have shown 
that spironolactone treatment increases nitric oxide bioactivity and improves endothelial 
dysfunction in patients with congestive heart failure (Farquharson & Struthers, 2000). However, 
due to its adverse effects such as gynecomastia, a more potent and selective MR antagonist, 
eplerenone was developed (Takeda, 2009). Eplerenone, a selective antagonist of 
mineralocorticoid receptor is as equipotent as enalapril, an ACEI, in the treatment of 
hypertension and more potent in reducing albuminuria (Williams et al., 2004). Eplerenone when 
used in combination with ACEIs/ARBs is effective in reducing albuminuria in type II diabetic 
nephropathy patients (Sato et al., 2003). There was a phenomenal decrease in the blood pressure 
in Japanese patients treated with eplerenone compared to other anti-hypertensive agents such as 
ARBs, ACEIs, β-blockers or calcium blockers given either individually or in combination 
(Nishiyama et al., 2010a).  
Diabetic nephropathy 
Diabetic nephropathy is one of the microvascular complications of type II diabetes and a leading 
cause for the development of end stage renal disease (Gurley & Coffman, 2010). Albuminuria, 
hypertension and impaired renal function are the characteristics of diabetic nephropathy. Strict 
controls of blood pressure, glycemia as well as therapeutic approaches aimed at blocking the 
RAS are strategies known to improve symptoms of diabetic nephropathy (Tan et al., 2010). 
Molecular and structural abnormalities in the podocyte slit diaphragm of the glomerular 
epithelial cell leads to the development of proteinuria that further promotes mesangial cell 
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proliferation and thickening of glomerular basement membrane (Ziyadeh & Wolf, 2008; 
Langham et al., 2002). Ang II plays a key role in the pathogenesis and progression of diabetic 
kidney injury via depletion of glomerular nephrin and increase in glomerular pore size (Bichu et 
al., 2009). Thus, blockade of Ang II is considered crucial in the treatment of diabetic 
nephropathy. Blockade of RAS with ACEIs and ARBs imparts renoprotection via anti-
inflammatory and anti-fibrotic mechanisms (Hauser & Horl, 2001). ACEIs usually reduce the 
formation of Ang II from ACE, as a result effects of Ang II such as vasoconstriction, increased 
cell growth, progressive glomerular sclerosis can be decreased (Tan et al., 2010). ARBs, on the 
other hand block AT1R through which Ang II exerts its effects and stimulates AT2R mediating 
effects opposite to AT1R (Burns, 2000). Due to the inadequate sensitivity and specificity of the 
methods used to diagnose diabetic nephropathy there is a need for the identification of 
noninvasive and early biomarkers to diagnose and treat this disease (Wu et al., 2010).  
Animal models of diabetic nephropathy 
Limited progress has been made in understanding the factors that contribute to the development 
of diabetic nephropathy. Hence, development of an ideal animal model which mimics the human 
disease is essential for a better understanding. In the year 2005, Animal Models of Diabetic 
Complications Consortium (AMDCC) published the phenotyping standards and validation 
criteria for the available murine models of diabetic nephropathy (Breyer et al., 2005). According 
to AMDCC, criteria for mouse model of diabetic nephropathy includes greater than 50% decline 
in the GFR, greater than 10 fold increase in the albuminuria compared to controls, advanced 
mesangial matrix expansion and thickening of glomerular basement membrane by more than 
50% over baseline tubulointerstitial fibrosis (Brosius, III et al., 2009). There are several mouse 
models of diabetic nephropathy to date. The widely used model is “db/db” which is a mouse 
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model for type II diabetes. These mice have a mutation deletion in the leptin receptor which 
makes them more susceptible to diabetic complications (Sharma et al., 2003). Albuminuria, 
mesangial matrix expansion and podocyte loss leads to the development of diabetic nephropathy 
in these mice (Brosius, III et al., 2009; Sharma et al., 2003; Susztak et al., 2006). Thus, they pose 
to be a good model for studying the early changes of diabetic nephropathy. Another mouse 
model for diabetic nephropathy is the type I diabetic OVE26 mouse that is characterized by 
increased expression of calmodulin in pancreatic β cells (Xu et al., 2010). Similar to db/db mice, 
these mice also demonstrate increased albumin excretion, decreased podocyte number and 
increased mesangial matrix. However, due to some limitations, they can only be used for 
studying the advanced features of diabetic nephropathy (Reiniger et al., 2010). One of the major 
mouse models for diabetic nephropathy is eNOS deficient db/db or 
eNOS-/-
 db/db mouse 
characterized by type II diabetes, hypertension, obesity, albuminuria and mesangial expansion 
(Zhao et al., 2006a; Mohan et al., 2008). Any abnormality in NO production plays a major role in 
renal injury (Komers & Anderson, 2003; Prabhakar, 2005). Similarly, two independent groups 
generated type I diabetic mouse model with deficiency in eNOS activity by injecting high and 
multiple low doses of streptozotocin (STZ) (Nakagawa et al., 2007) eNOS
-/-
 diabetic mice 
depicted a 10- fold increase in albuminuria with low dose STZ and 40 fold increase in 
albuminuria with high dose STZ. Similarly, various other murine models such as AKITA, BTBR 
ob/ob mice were developed for a better predictability of the factors that contribute to diabetic 
nephropathy (Alpers & Hudkins, 2011).  
Renoprotection of ACE2 
In type II diabetic patients, kidney disease is often associated with attenuation in renal ACE2 
mRNA and protein expression (Reich et al., 2008). Immunostaining of ACE2 decreased in 
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glomerulus of diabetic mice whereas ACE was increased compared to control mice (Ye et al., 
2006). Administration of ACE2 inhibitor MLN – 4760 increased albuminuria, glomerular 
mesangial matrix expansion and fibronectin deposition in glomerulus of db/db and STZ mice 
(Ye et al., 2006; Soler et al., 2007). Ang II dependent blood pressure increased substantially in 
ACE2 - deficient mice than in wild type mice (Gurley et al., 2006). Treatment with MLN-4760, 
decreased renal cortical ACE2 activity in a mouse model of CKD (5/6 nephrectomy or 5/6 Nx 
mice) (Dilauro et al., 2010). In mice lacking ACE2, glomerulosclerosis is associated with 
impairment in the glomerular filtration barrier which further increases the urinary albumin 
excretion (Oudit et al., 2006). Human recombinant ACE2 improved kidney function in type 1 
diabetic AKITA mice by suppressing the Ang II induced activation of NADPH oxidase activity 
(Oudit et al., 2010).  
Urinary biomarkers 
Urine is one of the clinical samples used as a tool for the identification of biomarkers in the 
diagnosis and prognosis of disease because of its ready availability, simple and non invasive 
collection (Thongboonkerd, 2008). Urine is produced by glomerulus after filtration of plasma 
and most of  it is reabsorbed by the renal tubule (Decramer et al., 2008). Thus, only a small 
portion of it exits through the kidney (Decramer et al., 2008). Urine is a reservoir of many 
proteins and peptides which are stable and less complex (Wu et al., 2010). The changes in kidney 
and urogenital tract functions can be assessed by the amount and composition of these proteins in 
urine (Wu et al., 2010). Renal damage, oxidative stress, low grade inflammation and endothelial 
stress are the three main conditions responsible for the presence of biomarkers related to diabetes 
in the urine (Matheson et al., 2010).  
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Albuminuria 
Markers for diabetic nephropathy in the urine are a result of kidney damage, oxidative stress or 
inflammation and vascular damage (Matheson et al., 2010). Microalbuminuria was used as a 
marker for the diagnosis of diabetic nephropathy. Glomerulus of the kidney filters certain 
amount of low molecular weight proteins such as albumin from the plasma but most of it is 
reabsorbed back (Barratt & Topham, 2007). Microalbuminuria is a condition where the amount 
of albumin excreted per day is 30-300mg/day, which is not a detectable range (Barratt & 
Topham, 2007). Macroalbuminuria is a condition where the amount of albumin excreted exceeds 
300mg/day (Matheson et al., 2010). The kidney has already undergone significant damage by the 
time its detected (Barratt & Topham, 2007).  
Urinary RAS 
Intrarenal RAS plays a significant role in the pathogenesis of diabetic nephropathy (Kobori et al., 
2007). Angiotensinogen (AGT), a substrate of renin, is present in high concentrations in the 
urine of hypertensive patients and is formed in the proximal tubules of the kidney (Kobori et al., 
2009). Thus, this AGT could be used as a urinary marker to assess intrarenal RAS status in 
hypertensive patients (Kobori et al., 2009). Furthermore there was a positive correlation between 
urinary albumin, serum creatinine, sodium excretion and urinary AGT (Kobori et al., 2008). 
There is also an elevation of urinary AGT in chronic kidney disease (Kobori et al., 2008). All 
these observations make it a good urinary biomarker for determination of the severity of CKD 
(Kobori et al., 2008). 
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Other urinary biomarkers  
Many new biomarkers in urine were discovered of which fatty acid binding protein 1 (FABP1) is 
one example (Noiri et al., 2009).  
Adiponectin is a protein hormone exclusively produced in adipocytes with insulin sensitizing, 
anti inflammatory and anti atherosclerotic effects (Kadowaki & Yamauchi, 2005). Diabetes 
induced stress in the glomerular capillaries causes adiponectin to shed off from the endothelial 
surface into the urine (von Eynatten et al., 2009). Thus it can be used as a urinary biomarker for 
indicating the vascular damage in type 2 diabetes (von Eynatten et al., 2009).  
Another biomarker of kidney disease is the pigment epithelium derived factor, a serine protease 
inhibitor used for detection of diabetic nephropathy (Chen et al., 2010). 
Thiazolidinediones 
Thiazolidinediones (TZDs) are synthetic ligands which have high affinity towards  subunit of 
Peroxisome proliferator activated receptor (PPAR) and are clinically used to increase insulin 
sensitivity in type II diabetic patients (Weatherford et al., 2007). PPAR is a ligand activated 
transcription factor known to be involved in causing inflammation, cancer, Alzheimer’s disease, 
diabetes and cardiovascular diseases such as hypertension and atherosclerosis (Weatherford et 
al., 2007). They are found mainly in adipose tissue cells but are also found in vascular 
endothelial cells, vascular smooth muscle cells, macrophages, renal glomerular and tubular cells 
(Sarafidis & Bakris, 2006). Apart from strict glycemic control PPAR agonists also control blood 
pressure by directly acting on the blood vessel (Weatherford et al., 2007). Studies showed that 
PPAR decreased Ang II induced elevation of blood pressure in rats, improved endothelial 
function in double- transgenic mice and caused down regulation of AT1 receptor gene 
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expression in vascular smooth muscles (Diep et al., 2002; Ryan et al., 2004; Sugawara et al., 
2001).  
Renoprotection of thiazolidinediones 
Association between metabolic syndrome and insulin resistance coupled with elevated urinary 
albumin excretion has been known and studied for the past many years (Sarafidis et al., 2006). 
Apart from their insulin sensitizing properties, TZDs also showed attenuation of blood pressure 
and triglycerides as well as redistribution of body fat from the central component (Lebovitz & 
Banerji, 2001; Stolar & Chilton, 2003). Accumulating evidence suggests that TZDs exhibit 
renoprotective effects. Chronic treatment with rosiglitazone in patients with type II diabetes and 
hypertension  reduced urinary albumin excretion by 30% and 60% in patients with type II 
diabetes and microalbuminuria respectively (Pistrosch et al., 2005; Sarafidis et al., 2005). The 
mechanism of action of renoprotective effects of TZDs is not clear. Reduction in blood glucose 
and elevated insulin levels, inhibition of tubular and glomerular cell proliferation, reduction of 
TGF-β, blood pressure (BP) attenuation, reduction in oxidative stress in the kidney and 
prevention of the activation of the RAS are some of the effects of TZDs contributing to the 
attenuation of urinary albumin excretion (UAE) and renal injury (Sarafidis & Bakris, 2006). 
According to many In vitro studies, TZDs especially rosiglitazone, decreased production of Ang 
I and II from human subcutaneous adipocytes and also attenuated expression of both AT1R 
mRNA and protein expression in vascular smooth muscle cells (Takeda et al., 2000; Harte et al., 
2005; Sugawara et al., 2001). There are not many lines of evidence demonstrating the beneficial 
effects of rosiglitazone on RAS blockade in vivo. Rosiglitazone and pioglitazone inhibited the 
detrimental effects of Ang II infusion such as endothelial dysfunction, development of 
hypertension, upregulation of AT1 receptors in blood vessels of rats (Diep et al., 2002).TZDs 
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show  beneficial effects on the vasculature by improving endothelial function and reducing 
inflammation (Campia et al., 2006). However, recently safety of TZDs was questioned because 
of the claims that they increased myocardial infarction (Nissen & Wolski, 2007). Rosiglitazone 
increase tissue insulin sensitivity and is shown to be protective against worsening of nephropathy 
and hypertension in diabetes. Mechanisms underlying protection at the renal level is not fully 
elucidated. One of goal of the present study is to investigate the effect of normalizing 
hyperglycemia on renal ACE2 and albuminuria in db/db diabetic mice.  
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2. HYPOTHESIS AND SPECIFIC AIMS 
2.1.  Hypothesis 
Increase of plasma aldosterone levels in db/db mice downregulates renal ACE2 and contributes 
to development of albuminuria. Treatment with MR blockers and/or strict glycemic control will 
correct this imbalance and protect against albuminuria. 
2.2.  Specific aims 
1. To test the hypothesis that hyperglycemia increases plasma aldosterone levels in db/db mice 
which leads to albuminuria and this could be corrected by normalizing blood glucose levels 
with the antidiabetic medication rosiglitazone, or by giving MR antagonist spironolactone. 
 
2. To test the hypothesis that spironolactone ameliorates albuminuria in db/db mice through 
increase in renal ACE2. 
 
3. To test the hypothesis that strict glycemic control using rosiglitazone imparts renal protection 
in db/db mice through increase in renal ACE2. 
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3. MATERIALS AND METHODS 
Animals 
Male (5-6 wk) db/db diabetic mice with background strain C57BL/KsJ (BKS.Cg-Dock7
m
 +/+ 
Lepr
db
/J) and their age-matched non-diabetic lean control mice (db/m) were purchased from 
Jackson Laboratories (Bar Harbor, ME). Mice were housed individually at room temperature 
(22C) in a 12:12 hour light/dark cycle. db/db mice serve as a good model for type II diabetes. 
These mice have point mutation in the diabetic (db) gene that encodes for a point mutation in the 
leptin receptor gene leading to abnormal splicing and defective signaling of the adipocyte- 
derived hormone leptin (Chen et al., 1996). All experimental protocols were approved by WSU 
animal care and use committee. 
3.1. Chronic Treatment With Rosiglitazone And Spironolactone 
Five week old db/db and their age-matched lean control mice were randomly assigned to 
rosiglitazone (LKT laboratories, Inc. St. Paul, MN, USA) and spironolactone (Sigma Aldrich, St. 
Louis, MO) treatment. Each group consisted of 7-8 mice. Remaining mice from db/db and 
control groups were provided with normal chow. Rosiglitazone group was given 20 mg/kg/day 
rosiglitazone mixed in food pellets for 10 weeks. Spironolactone group received 100 mg/kg/day 
spironolactone mixed in food pellets for 10 weeks. To determine the changes in physiologic and 
metabolic parameters in treated and untreated groups both in normal and disease states, mice 
were regularly monitored for blood glucose, body weight, food intake, water intake and urine 
output over a duration of 8 weeks. After 10 weeks of treatment, mice were euthanized by 
decapitation and trunk blood was collected in ice-chilled heparinized tubes. Blood was 
centrifuged at 10,000 x g for 10 minutes at 4° C. Plasma was separated, aliquoted and stored at -
80° C. Tissues were collected on dry ice and stored at -80° C. 
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3.2.  Body composition measurement 
Body composition was measured using an ECHO MRI absolute body composition analyzer 
(Houston, TX, USA). After the instrument was calibrated, the body weight of the mouse was 
measured. Then the mouse was placed in a clear plastic cylinder and held in position with a 
plastic plunger to avoid any movements. This setup was placed inside the instrument and the 
measurements were taken. At the end of the measurement the mouse was placed back in its cage. 
 
3.3. Western blot analysis 
Mice were sacrificed by decapitation and kidneys were quickly removed and homogenized on 
ice in phosphate buffered saline (PBS) containing protease inhibitor (Complete lysis M, Roche 
diagnostics, Mannheim, Germany). Tissue homogenates were centrifuged at 10,000 x g for 10 
min at 4° C to remove cellular debris. Total protein content was determined in supernatant using 
BSA as a standard and BioRad reagent (BioRad, Hercules, CA). Fifty microliters (µl) of tissue 
lysate was added to 50 µl sample loading buffer (8% SDS, 125 mmol/L Tris-HCl, pH-6.8, 20% 
glycerol, 0.02% bromophenol blue, 100 mmol/L dithiothreitol) and boiled for 10 minutes. 
Protein (50-100µg) was loaded into the wells of a 10% SDS-PAGE gel and separated by 
electrophoresis for 1 hour. Proteins on gel were then transferred (Bio-Rad transfer apparatus, 
Hercules, CA) to a 0.2 µm PVDF membrane (Millipore, MA). The membrane was blocked for 1 
hour with 10% non-fat milk in 10 mM Tris buffered saline with Tween 20 (TBS-T) at room 
temperature (RT). For analysis of  MR, NEP and ACE2  membranes were probed over night at 
4°C with rabbit anti-MR antibodies (1:250, Santa Cruz, CA), goat anti-NEP (1:500, R&D, MN) 
and goat anti-ACE2 (1:1000, R&D, MN) respectively. Primary antibodies were diluted in 5% 
non-fat milk in TBS-T. The membrane was then washed with TBS-T buffer 3 times for 5 
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minutes at RT. The membrane was then incubated with diluted horse radish peroxidase 
conjugated to donkey anti-rabbit (dilution 1:20000 in TBS-T, Jackson Immunoresearch, PA), 
donkey anti goat (1:2000 in TBS-T, R&D) or donkey anti-mouse (dilution 1:40000 in TBS-T, 
Jackson immunoresearch, PA) secondary antibodies at RT for 1hour. The membrane was washed 
3 times for 3 minutes using TBS-T buffer. Blots were detected using supersignal 
chemiluminescent substrate and visualized by exposing the membrane for 1 minute using a 
Fujifilm image analyzer (LAS 3000, image Quant, Sunnyvale, CA). The relative amounts of 
proteins of interest were determined by normalizing to β-actin. Western blot images were 
quantified using Image Quant TL software using β-actin as an internal loading control. 
 
3.4.  Immunohistochemistry 
Mice were injected with Euthasol-130mg/ml (0.05ml/40g mouse).They were perfused 
transcardially with ice cold PBS to flush out the blood and then with 4% Paraformaldehyde for 
10 min. Paraffin sections were deparafinized by washing in xylene for 5 min and subsequent 
hydration with 100%, 95%, 70%, 50% and 30% ethanol for 5min each. Sections were then rinsed 
with distilled H2O and PBS. Rinsed sections were transferred to water bath containing 10mM 
sodium citrate and boiled for 30 minutes. Boiled sections were blocked using 3% normal horse 
serum (diluted in PBS containing 0.1% Triton-X) for 1hour at 4
o
C. Primary antibodies MR 
(1:250, Santacruz, CA), NEP (1:500, R&D, MN) and ACE2 (1:500, R&D, MN) were diluted in 
3% normal horse serum and sections were incubated in diluted primary antibodies overnight at 
4
o
C. The sections were then washed with PBS three times and incubated with their respective 
CY
3
 secondary antibodies (Jackson Immunoresearch, PA) for 2 hours at 4
o
C. MR was incubated 
with donkey anti - rabbit secondary antibody conjugated with CY
3 
fluorescent dye and ACE2, 
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NEP were incubated with donkey anti - goat secondary antibody conjugated with CY
3 
fluorescent dye. Slides were air dried and mounted using a vectashield mounting medium 
(Vector, Burlingame, CA). Images were taken using a fluorescence microscope (Optronics, 
Goleta, CA).  
3.5. Measurement of blood glucose levels 
FreeStyle® Blood Glucose Test Strips and FreeStyle Lite® Blood Glucose Monitoring System 
(Abbott, CA) was used to determine blood glucose levels on a drop of tail blood collected 
between 10 am and midday, or at intervals thereafter as indicated. A cut was made at the tip of 
the tail to draw blood samples for measurement. Values were expressed in mg/dL. 
3.6. Glucose tolerance test 
In order to study the glucose handling in mice, an intra-peritoneal glucose tolerance test was 
performed. Mice were fasted overnight for 16 hours. Fasting blood glucose levels were measured 
after the end of the fasting period. Mice were then injected with 1.5 gm/kg glucose dissolved in 
water. Blood samples were drawn at 0, 15, 30, 45, 60, 90 and 120 minutes and diluted in 300µl 
water and 25µl lysis buffer. Glucose concentration was determined using glucose 
oxidase/peroxidase reagent kit (Sigma, St. Louis, MO). 
3.7. Plasma hormone and lipids measurement 
Plasma samples from the treated and untreated db/db diabetic mice and their age matched lean 
control mice were collected and analyzed for insulin, glucose, adiponectin, cholesterol and 
triglyceride levels at the Mouse Metabolic Phenotyping Centre (Cincinnati, OH). 
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3.8. Plasma aldosterone levels measurement 
Plasma aldosterone levels were measured using an aldosterone ELISA immune assay kit 
purchased from Alpco diagnostics (Salem, NH). Absorption was read at 450nm using Fusion
R 
Packard plate reader.  
3.9. ACE2 activity 
ACE2 activity was measured using the substrate Mca-APK-Dnp. It involves the principle of 
emission of fluorescence from the Mca substrate (quenched by Dnp group) upon cleavage by 
ACE2. After cleavage fluorescence was detected at excitation: 328 nm and Emission: 393nm 
(Fusion
R 
Packard plate reader). ACE2 activity was measured in presence of 10mM lisinopril 
(ACE inhibitor), to prevent any interference from ACE. Four microliters (32-40 µg protein) of 
kidney lysate or 5-20 µl (40-60 µg protein) of urine sample were incubated with substrate in a 
buffer (50mM Tris, 5mM ZnCl2, 150mM NaCl2 and 10µM lisinopril). The plate was read at 0, 1, 
2, 3, 4 and 8 hours. The results were expressed as pmoles/hr/µg protein of cleaved substrate. 
3.10. Urine collection 
Mice were put in metabolic cages for 24 hours collection of urine with free access to food and 
water. A total of 20 µl of protease inhibitor (Roche Diagnostics, IN) was added to each sample 
during the 24 hours collection. Urine samples were centrifuged at 10,000 x g for 3 minutes at 4° 
C to remove debris. Urine samples were then aliqouted and stored at -80° C for later use. 
3.11. Urinary albumin assay 
To monitor kidney function, quantitative estimation of urinary albumin was performed using a 
kit purchased from the Bethyl Laboratories (Montgomery, TX). A 96 well plate was coated with 
goat anti-mouse albumin antibody (100 μl) diluted 1:100 in carbonate-bicarbonate buffer for 1 
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hour at RT. After incubation, the antibody solution was aspired from each well and washed with 
wash buffer (250 μl, TBS-T) 4 times. Blocking buffer (Tris buffered saline with 1% BSA, 200 
μl) was added to each well and the plate was incubated overnight at 4˚C. The next day, plate was 
washed 4X with TBS-T Standards were diluted according to the kit’s protocol. Urine samples 
(1μl) were diluted with 500 µl of conjugate buffer and 100 μl of diluted urine samples and 
standards were added to each well and incubated at RT for 1 hour. Plate was washed 4X with 
TBS-T. Diluted HRP conjugated secondary antibody (1:35000 in conjugate buffer, 100 µl) was 
added to each well and  incubated for 1 hour at RT. Wells were then washed 4X with TBS-T. 
Equal volumes of TMB substrate A and substrate B (KPL, Gaithersburg, MD) were mixed and 
100 μl of this substrate mix was added to each well and incubated in dark for about 30 minutes. 
The reaction was stopped by adding 2N H2SO4 (100 μl) to each well. Plate was finally read at 
450 nm in Fusion
R
 Packard plate reader. 
3.12. Urinary creatinine assay 
Urinary creatinine assay was performed using a kit purchased from Quidel (San Diego, CA). The 
excretion rate of creatinine in a normal individual is relatively constant. Thus, urinary creatinine 
levels are useful in detecting renal disease and estimating the extent of impairment of renal 
function. The assay is based on modified Jaffe reaction where alkaline picrate forms a colored 
solution in presence of creatinine. Samples and standards were diluted 1:40 with distilled water. 
Fifty microliters of diluted samples and standards were added to 96 well plate followed by 
addition of 150 μl of color reagent (7 mL picric acid + 1 mL 1N NaOH). This mixture was 
incubated for 30 minutes at RT. Plate was read at 490 nm (FusionR Packard plate reader). The 
intensity of the color produced is directly proportional to the amount of creatinine present in the 
sample. 
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3.13. Statistical analysis 
Statistical analysis was performed using Graph pad prism 5.01 and statistica software (v.10). All 
data were expressed as mean ± SEM. The differences in blood glucose, body weight, food 
intake, water intake, absolute body fat, lean mass and total body water were assessed by repeated 
measures two-way ANOVA followed by Bonferroni’s multiple comparison test. For more than 
two groups one-way and two-way ANOVAs were used. Unpaired student’s t-test was used to 
evaluate the differences between two groups. A value of p<0.05 was considered statistically 
significant. 
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Table 1: Age dependent changes in metabolic parameters of lean control and db/db diabetic mice.  
 
Mice strain Lean control db/db Lean control db/db Lean control db/db 
Age (weeks) 6 6 9 9 12 12 
Group size (n) 7 6 7 6 7 6 
Body weight (g) 22.1±0.7 32.2±1.1* 25.1±0.5 40.9±0.7* 27.1±0.4 40.3±0.6* 
Blood glucose (mg/dL) 117.8±3.2 348.2±29.9* 124.8±4.7 463.8±37.9* 135.3±3.2 575.6±20.2* 
Food intake 
(g/day/mouse) 3.4±0.2 6.3±0.8* 7.3±0.2 12.7±0.4* 3.5±0.1 6.8±0.8* 
Water intake 
(ml/day/mouse) 8.1±0.2 15.4±3.1 8.8±0.6 30.7±2.1* 6.4±0.3 31.4±3.7* 
Absolute body fat (g) ND ND 4.2±0.3 22.0±0.7* 5.1±0.5 21.3±0.4* 
Absolute lean mass (g) ND ND 18.5±0.3
#
 16.0±0.8 18.5±0.2
#
 15.6±0.4 
Total body water (g) ND ND 15.5±0.3
#
 13.6±0.3 15.7±0.2
#
 13.5±0.3 
 
Values represent mean±SEM. *p<0.05 Vs age-matched lean control mice and 
#
 p<0.05 Vs age-matched db/db mice were considered 
statistically significant. ND means not determined. 
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Table 2: Age dependent changes in renal function parameters of lean control and db/db diabetic mice. 
 
 
 
 
 
 
 
 
Values represent mean±SEM. *p<0.05 Vs age-matched lean control mice were considered statistically significant. 
Mice strain Lean control db/db Lean control db/db Lean control db/db 
Age (weeks) 5 5 10 10 14 14 
Group size (n) 9 9 6 6 6 6 
Albumin (mg/day) 0.1±0.004 0.2±0.01* 0.09±0.02 1.3±0.02* 0.05±0.005 1.5±0.04* 
Total protein excretion 
(mg/day) 
2.7±0.1 1.2±0.1 4.5±0.7 21.4±3.0* 4.6±0.5 27.0±3.0* 
Urine volume (ml/day) 1.0±0.004 2.6±0.2* 0.8±0.12 12.6±1.6* 0.9±0.092 23.6±1.2* 
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Table 3: Effect of rosiglitazone on plasma hormone and lipid parameters in lean control and db/db diabetic mice. 
 
Values represent mean±SEM *p<0.05 Vs age-matched db/db mice and 
#
 p<0.05 Vs age-matched lean control mice were considered 
statistically significant. 
 
Mice strain Lean control Lean + rosiglitazone db/db db/db + rosiglitazone 
Age (weeks) 16 18 16 16 
Duration (weeks) 10 13 10 10 
Group size (n) 7 7 7 8 
Plasma Insulin (ng/ml) 1.73±0.2 1.2±0.3 5.9±1.7
#
 4.3±0.4 
Plasma adiponectin (µg/ml) 2.0±0.06 5.5±0.40
#
 1.4±0.1
#
 9.1±1.5* 
Plasma leptin (ng/ml) 4.0±0.4 7.1±0.9 14.6±1.4
#
 38.1±3.7* 
Plasma glucagon (ng/ml) 0.07±0.01 0.06±0.01 0.4±0.05
#
 0.2±0.03* 
Plasma triglyceride (mg/dl) 94.5±5.07 74.9±6.2 274.0±24.7
#
 65.9±6.7* 
Plasma cholesterol (mg/dl) 110.3±3.95 76.1±2.25 136.9±6.3
#
 158.6±8.9 
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Table 4: Effect of spironolactone on plasma hormone and lipid parameters in lean control and db/db diabetic mice.  
Mice strain Lean control Lean + spironolactone db/db db/db + spironolactone 
Age (weeks) 16 16 16 16 
Duration (weeks) 10 10 10 10 
Group size (n) 7 7 7 7 
Plasma Insulin (ng/ml) 1.7±0.2 1.7±0.06 5.9±1.7
#
 2.1±0.6* 
Plasma adiponectin (µg/ml) 2.0±0.1 1.7±0.1 1.4±0.1
#
 1.2±0.1 
Plasma leptin (ng/ml) 4.0±0.4 4.9±0.4 14.6±1.4
#
 14.7±1.4 
Plasma glucagon (ng/ml) 0.07±0.01 0.08±0.01 0.4±0.05
#
 0.5±0.07 
Plasma triglyceride (mg/dl) 94.5±5.1 126.9±7.7 274.0±24.7
#
 179.2±21.1* 
Plasma cholesterol (mg/dl) 110.3±4.0 114.6±2.7 136.9±6.3
#
 154±9.9 
 
Values represent mean±SEM. *p<0.05 Vs age-matched db/db mice and 
#
 p<0.05 Vs age-matched lean control mice were considered 
statistically significant.
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Figure 1:  Blood glucose levels in lean control mice (n=7), lean + rosiglitazone mice (n=7), 
db/db mice (n=6), db/db + rosiglitazone mice (n=8) at 0-7 weeks during rosiglitazone treatment. 
Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that treatment 
caused a significant decrease in blood glucose levels of db/db + rosiglitazone mice [F (3, 54) = 
176.04], p<0.0001. Similarly duration of treatment showed a significant decrease in blood 
glucose levels of db/db + rosiglitazone mice [F (21, 54) = 16.34], P<0.0001. Data are 
represented as mean±SEM of group size (n=6-8).  
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Figure 2: Body weights measurement in lean control mice (n=7), lean + rosiglitazone mice 
(n=7), db/db mice (n=6), db/db + rosiglitazone mice (n=8) at 0-7 weeks during rosiglitazone 
treatment. Repeated measures two-way ANOVA using Bonferroni’s posthoc test showed that 
treatment resulted in a significant increase in body w eights of db/db + rosiglitazone mice [F (3, 
54) = 306.03], p<0.0001. Similarly duration of treatment showed a significant increase in body 
weights of db/db + rosiglitazone mice [F (21, 54) = 67.55], p<0.0001. Data are represented as 
mean±SEM of group size (n=6-8).  
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Figure 3: Food intake measurement in lean control mice (n=7), lean + rosiglitazone mice (n=7), 
db/db mice (n=6), db/db + rosiglitazone mice (n=8) at 1-7 weeks during rosiglitazone treatment. 
Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that treatment 
had no effect on food intake of db/db + rosiglitazone mice. Similarly duration of treatment 
showed no effect on food intake of db/db + rosiglitazone mice. Data are represented as 
mean±SEM of group size (n=6-8).  
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Figure 4: Water intake measurement in lean control mice (n=7), lean + rosiglitazone mice (n=7), 
db/db mice (n=6), db/db + rosiglitazone mice (n=8) at 1-7 weeks during rosiglitazone treatment. 
Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that treatment 
significantly decreased water intake of db/db + rosiglitazone mice [F (3, 144) = 93.733], 
p<0.0001. Similarly duration of treatment showed significant decrease in water intake of db/db + 
rosiglitazone mice [F (18, 144) = 5.492], p<0.0001. Data are represented as mean±SEM of group 
size (n=6-8).  
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Figure 5: Absolute body fat measurement in lean control mice (n=7), lean + rosiglitazone mice 
(n=7), db/db mice (n=7), db/db + rosiglitazone mice (n=8) at 3-7 weeks during rosiglitazone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
treatment showed significant increase in absolute body fat of  lean + rosiglitazone and db/db + 
rosiglitazone mice [F (3, 63) = 985.20], p<0.0001. However duration of treatment showed no 
effect on absolute body fat of lean + rosiglitazone but increased absolute body fat of db/db + 
rosiglitazone mice [F (9,63) = 15.75], p<0.0001. Data are represented as mean±SEM of group 
size (n=7-8).  
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Figure 6: Absolute lean mass measurement in lean control mice (n=7), lean + rosiglitazone mice 
(n=7), db/db mice (n=6), db/db + rosiglitazone mice (n=8) at 3-7 weeks during rosiglitazone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
treatment resulted in a significant increase in absolute lean mass of  db/db + rosiglitazone mice 
[F (3,63) = 39.90], p<0.0001. However, duration of treatment showed no effect on absolute lean 
mass of db/db + rosiglitazone mice. Data are represented as mean±SEM of group size (n=6-8). 
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Figure 7: Total body water measurement in lean control mice (n=7), lean + rosiglitazone mice 
(n=7), db/db mice (n=6), db/db + rosiglitazone mice (n=8) at 3-7 weeks during rosiglitazone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
treatment caused significant increase in total body water of  db/db + rosiglitazone mice [F (3,60) 
= 24.47], p<0.0001. However, duration of treatment showed no effect on total body water of 
db/db + rosiglitazone mice. Data are represented as mean±SEM of group size (n=6-8). 
 
 
3 4 6 7
12
14
16
18
Lean control
db/db
db/db + Rosiglitazone
Lean + Rosiglitazone
Time after treatment (Weeks)
T
o
ta
l b
o
d
y
 w
a
te
r 
(g
m
s
/m
o
u
s
e
)
37 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Blood glucose levels in lean control mice (n=7), lean + spironolactone mice (n=7), 
db/db mice (n=6), db/db + spironolactone mice (n=8) at 0-7 weeks during spironolactone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
treatment had no effect on blood glucose of db/db + spironolactone mice. Similarly duration of 
treatment showed no effect on blood glucose of db/db + spironolactone mice. Data are 
represented as mean±SEM of group size (n=6-8). 
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Figure 9: Body weight measurement in lean control mice (n=7), lean + spironolactone mice 
(n=7), db/db mice (n=6), db/db + spironolactone mice (n=8) at 0-7 weeks during spironolactone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
treatment had no effect on body weights of db/db + spironolactone mice. Similarly duration of 
treatment showed no effect on body weights of db/db + spironolactone mice. Data are 
represented as mean±SEM of group size (n=6-8). 
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Figure 10: Food intake measurement in lean control mice (n=7), lean + spironolactone mice 
(n=7), db/db mice (n=6), db/db + spironolactone mice (n=8) at 1-7 weeks during spironolactone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
treatment had significant increase in food intake of lean + spironolactone and db/db + 
spironolactone mice [F (3,100) = 72.663], p<0.0001. However duration of treatment showed no 
effect on food intake of lean + spironolactone and db/db + spironolactone mice. Data are 
represented as mean±SEM of group size (n=6-8). 
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Figure 11: Water intake measurement in lean control mice (n=7), lean + spironolactone mice 
(n=7), db/db mice (n=6), db/db + spironolactone mice (n=8) at 1-7 weeks during spironolactone 
treatment. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed no 
effect on water intake of lean + spironolactone and db/db + spironolactone mice. Similarly 
duration of treatment showed no effect on food intake of lean + spironolactone and db/db + 
spironolactone mice. Data are represented as mean±SEM of group size (n=6-8). 
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Figure 12: Absolute body fat measurement in lean control mice (n=7), db/db mice (n=6), db/db 
+ spironolactone mice (n=8) at 4-7 weeks during spironolactone treatment. Repeated measures 
two-way ANOVA using a Bonferroni’s posthoc test showed no effect on absolute body fat of 
db/db + spironolactone mice. Similarly duration of treatment showed no effect on absolute body 
fat of db/db + spironolactone mice. Data are represented as mean±SEM of group size (n=6-8). 
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Figure 13: Absolute lean mass measurement in lean control mice (n=7), db/db mice (n=6), db/db 
+ spironolactone mice (n=8) at 4-7 weeks during spironolactone treatment. Repeated measures 
two-way ANOVA using a Bonferroni’s posthoc test showed no effect on absolute lean mass of 
db/db + spironolactone mice. Similarly duration of treatment showed no effect on absolute lean 
mass of db/db + spironolactone mice. Data are represented as mean±SEM of group size (n=6-8). 
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Figure 14: Total body water measurement in lean control mice (n=6), db/db mice (n=6), db/db + 
spironolactone mice (n=8) at 4-7 weeks during spironolactone treatment. Repeated measures 
two-way ANOVA using a Bonferroni’s posthoc test showed no effect on total body water of 
db/db + spironolactone mice. Similarly duration of treatment showed no effect on total body 
water of db/db + spironolactone mice. Data are represented as mean±SEM of group size (n=6-8). 
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Figure 15: There is an increase in the plasma aldosterone levels of the 16weeks old db/db mice 
(n=7) compared to their age-matched lean control mice (n=9). **p<0.001 Vs age-matched lean 
control mice. Each bar represents mean±SEM of group size (n=7-9).   
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Figure 16: There is an increase in the renal ACE2 activity of 16 weeks old db/db mice (n=6) 
compared to their age-matched lean control mice (n=6). ***p<0.0001 Vs age-matched lean 
control mice. Each bar represents mean±SEM of group size (n=6). 
 
 
 
 
 
 
Figure 17: There is an increase in the urinary ACE2 activity of 14 weeks old db/db mice (n=6) 
compared to their age-matched lean control mice (n=7). 
#
p<0.05 Vs age-matched lean control 
mice. Each bar represents mean±SEM of group size (n=6-7). 
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Figure 18: Glucose tolerance test was performed in rosiglitazone treated (20 mg/kg/day for 8 
weeks) and untreated lean control and db/db mice. One-way ANOVA of area under curve 
showed that rosiglitazone significantly improved the glucose tolerance in the db/db + 
Rosiglitazone (n=8) mice compared to db/db mice (n=6). 
#
p<0.05 Vs untreated db/db mice.    
*** p<0.001 Vs age-matched lean control mice. Each bar represents mean±SEM of group size 
(n=6-8).  
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Figure 19: One-way ANOVA showed that 8 weeks after treatment commenced there is a 
significant decrease in urinary glucose excretion in the db/db + rosiglitazone mice (n=8) 
compared to untreated db/db mice (n=6). **p<0.001 Vs untreated db/db mice. Each bar 
represents mean±SEM of group size (n=6-8). 
 
 
 
 
 
Figure 20: One-way ANOVA showed that 8 weeks after treatment commenced there is a 
significant decrease in the urinary glucose excretion in the db/db + spironolactone mice (n=7) 
compared to untreated db/db mice (n=6). *p<0.05 Vs untreated db/db mice. Each bar represents 
mean±SEM of group size (n=6-7). 
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Figure 21: Urinary albumin excretion in rosiglitazone treated and untreated db/db mice 4 weeks, 
6 weeks and 8 weeks after the commencement of treatment. Repeated measures two-way 
ANOVA using a Bonferroni’s posthoc test showed that treatment resulted in a significant 
decrease in urinary albumin excretion of db/db + rosiglitazone mice [F (1, 20) = 36.004], 
p<0.0001. Similarly, duration of treatment showed a significant decrease in urinary albumin 
excretion of db/db + rosiglitazone mice after 4 weeks, 6 weeks and 8 weeks of treatment [F (2, 
20) = 7.70], p<0.001. Each bar represents mean±SEM of group size (n=6-7). 
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Figure 22: Urinary albumin excretion in spironolactone treated and untreated db/db mice 4 
weeks, 6 weeks and 8 weeks after the commencement of treatment. Repeated measures two-way 
ANOVA using a Bonferroni’s posthoc test showed that treatment resulted in a significant 
decrease in urinary albumin excretion of db/db + spironolactone mice after 8 weeks of treatment 
[F (1, 14) = 10.4], p<0.01. However, duration of treatment had no effect on urinary albumin 
excretion of db/db + spironolactone mice. Each bar represents mean±SEM of group size (n=6-7). 
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Figure 23: One-way ANOVA showed that 8 weeks after treatment commenced there is a 
significant decrease in the urinary protein excretion in the db/db + rosiglitazone mice (n=8) 
compared to untreated db/db mice (n=6). **p<0.001 Vs untreated db/db mice. Each bar 
represents mean±SEM of group size (n=6-8). 
 
 
 
 
 
 
Figure 24: One-way ANOVA showed that 8weeks after treatment commenced there is no 
difference in the urinary protein excretion of db/db + spironolactone mice (n=7) compared to 
untreated db/db mice (n=6). Each bar represents mean±SEM of group size (n=6-7) 
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Figure 25: One-way ANOVA showed that there is no significant difference in the plasma 
aldosterone levels of the db/db + rosiglitazone mice (n=8) compared to untreated db/db mice 
(n=6) after 10 weeks of treatment. Each bar represents mean±SEM of group size (n=6-8). 
 
 
 
 
 
 
Figure 26: One-way ANOVA showed that there was a significant increase in the plasma 
aldosterone levels of the db/db + spironolactone mice (n=7) compared to untreated db/db mice 
(n=6) after 10 weeks of treatment. 
#
p<0.05 Vs untreated db/db mice and 
*
p<0.05 Vs untreated 
lean control mice. Each bar represents mean±SEM of group size (n=6-7). 
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Figure 27: One-way ANOVA showed that 10 weeks after treatment commenced there was a 
significant decrease in the renal ACE2 activity of the db/db + rosiglitazone mice (n=8) compared 
to untreated db/db mice (n=6). **p<0.001 Vs untreated db/db mice. Each bar represents 
mean±SEM of group size (n=6-8). 
 
 
 
 
 
 
Figure 28: One-way ANOVA showed that 10 weeks after treatment commenced there was a 
significant decrease in the renal ACE2 activity of the db/db + spironolactone mice (n=7) 
compared to untreated db/db mice (n=6). **p<0.001 Vs untreated db/db mice. Each bar 
represents mean±SEM of group size (n=6-7). 
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Figure 29: One-way ANOVA showed that 8 weeks after treatment commenced there was a 
significant decrease in the urinary ACE2 activity of the db/db + rosiglitazone mice (n=7) 
compared to untreated db/db mice (n=6). **p<0.001 Vs untreated db/db mice. Each bar 
represents mean±SEM of group size (n=6-7). 
 
 
 
 
 
 
Figure 30: One-way ANOVA showed that 8 weeks after treatment commenced there was no 
difference in the urinary ACE2 activity of db/db + spironolactone mice (n=7) compared to 
untreated db/db mice (n=6). Each bar represents mean±SEM of group size (n=6-7). 
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Figure 31: Unpaired t-test showed that there is a significant decrease in renal NEP and increase 
in renal MR protein expression in 16 weeks old db/db mice (n=6) compared to their age-matched 
lean control mice (n=7). *p<0.05 Vs age-matched lean control mice. Each bar represents 
mean±SEM of group size (n=6-7). 
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Figure 32: Unpaired t-test showed that there is a significant increase in renal NEP and decrease 
in renal MR protein expression in the treated db/db mice (n=8) compared to untreated db/db 
mice (n=6) after 10 weeks of treatment. *p<0.05 Vs untreated db/db mice. Each bar represents 
mean±SEM of group size (n=6-8). 
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Figure 33: One-way ANOVA showed that there was no significant difference in the ACE2 
protein expression in the treated db/db mice (n=8) compared to untreated db/db mice (n=6) after 
10 weeks of treatment. Each bar represents mean±SEM of group size (n=6-8). 
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Figure 34: Unpaired t-test showed that there was a significant decrease in the renal ACE2 
protein expression in the treated db/db mice (n=7) compared to untreated db/db mice (n=6) after 
10 weeks of treatment. However, spironolactone treatment did not change the renal MR protein 
expression. *p<0.05 Vs untreated db/db mice. Each bar represents mean±SEM of group size 
(n=6-7). 
* 
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Figure 35: A) Urinary ACE2 protein excretion increased significantly in 8 weeks old db/db mice 
compared to their age-matched lean control mice. B) Two weeks after treatment with 
rosiglitazone urinary ACE2 protein excretion decreased significantly compared to untreated 
db/db mice.  
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Figure 36: A) Decreased staining of renal NEP in db/db mice compared to lean control mice.   
B) Rosiglitazone increased NEP staining in db/db mice compared to untreated db/db mice. 
A 
B 
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Figure 37: PAS staining of kidney sections from lean control, treated and untreated db/db mice. 
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4. RESULTS 
4.1. General physiologic, metabolic and body composition parameters 
To examine the age-dependent changes in db/db mice, following parameters were monitored 
weekly. 
a) Blood glucose: There was an age-dependent increase in the blood glucose levels of the db/db 
mice. Juvenile (6 weeks) db/db mice had significantly higher blood glucose levels compared to 
lean control mice. Blood glucose levels were consistently increased over the 12 week study 
period (Table 1, *p<0.05, unpaired-t test). However there was no difference in the blood glucose 
levels of lean control mice. Moreover, db/db mice showed impaired glucose utilization in intra-
peritoneal glucose tolerance test (IGTT) suggesting insulin resistance (figure 18, ***p<0.001). 
b) Body weight: At 6 weeks, db/db mice gained more body weight compared to lean control mice 
(Table 1, *p<0.05). Body weights of db/db mice consistently increased over time and with age 
when compared to lean control mice (Table 1, *p<0.05, unpaired-t test). There was no difference 
in the body weights of lean control mice over time. 
c) Food intake: Young (6 weeks) db/db mice showed a significantly higher food intake 
compared to lean control mice (Table 1, *p<0.05). Similarly food intake of db/db mice increased 
significantly at 9 weeks and 12 weeks (Table 1, *p<0.05, unpaired-t test). 
d) Water intake: db/db mice showed higher water intake at 6 weeks compared to lean control 
mice but the effect is not statistically significant. However, after 6 weeks there was a significant 
increase in the water intake of db/db mice compared to their age-matched lean control mice 
(Table 1, *p<0.05, unpaired-t test). 
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e) Absolute body fat: There was a significant increase in the absolute body fat of db/db mice at 9 
weeks compared to the lean controls (Table 1, *p<0.05, unpaired-t test). Similar effect was also 
seen at 12 weeks (Table 1, *p<0.05). 
f) Absolute lean mass: db/db mice exhibited a significantly lower content of absolute lean mass 
at 9 weeks and 12 weeks compared to their age-matched lean control mice (Table 1, *p<0.05, 
unpaired t-test). 
g) Total body water: At 9weeks, db/db mice showed a significantly lower total body water 
content compared to lean control mice (Table 1, *p<0.05). Decrease in the total body water 
content was also seen at 12 weeks (Table 1, *p<0.05). 
 
4.2.  Plasma hormone and lipid parameters 
To assess hyperglycemia related hormonal changes, following parameters were measured.  
a) Plasma insulin: At 16 weeks db/db mice were hyperinsulinemic. There was a significant 
elevation in plasma insulin levels (lean: 1.73±0.2 and db/db: 5.9±1.7 ng/ml) in db/db mice 
compared to age-matched lean control mice (Table 3, 
#
p<0.05). 
b) Plasma leptin: There was a significant elevation in plasma leptin levels (lean: 4.0±0.4 and 
db/db: 14.6±1.4 ng/ml) of 16 weeks old db/db mice compared to lean control mice (Table 3, 
#
p<0.05). 
c) Plasma glucagon: At 16 weeks db/db mice had significantly higher plasma glucagon levels 
(lean: 0.07±0.01 and db/db: 0.4±0.05 ng/ml) compared to lean control mice (Table 3, 
#
p<0.05). 
d) Plasma adiponectin: There was a significant decrease in plasma adiponectin levels (lean: 
2.0±0.06 and db/db: 1.4±0.1µg/ml) of 16 weeks old db/db mice compared to lean control mice 
(Table 3, 
#
p<0.05). 
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e) Plasma triglycerides and cholesterol: At 16 weeks, there was a significant increase in plasma 
triglycerides and cholesterol levels in db/db mice compared to lean control mice (Table 3, 
#
p<0.05). 
 
4.3.  Assessment of renal function 
To assess the renal function, 24hr urine samples were collected and urinary albumin and total 
protein excretion were measured. 
a) Urinary albumin: At 5 weeks db/db mice demonstrated microalbuminuria and there was a 
significant difference between db/db mice and lean control mice (Table 2, *p<0.05). With aging, 
disease progressed and kidney function declined further. At 10 weeks and 14 weeks there was a 
significant increase in the urinary albumin excretion  in the obese db/db mice compared to age-
matched lean control mice (Table 2, *p<0.05). 
b) Urinary total protein: There was no significant difference in the urinary protein excretion of 
the db/db mice and lean control mice at 5weeks (Table 2). However, at 10 weeks there was a 
significant increase in the urinary protein excretion of db/db mice compared to lean controls 
(Table 2, *p<0.05). By 14 weeks, obese db/db mice showed a 10 fold increase in the urinary 
protein excretion compared to lean control mice (Table 2, *p<0.05). 
 
4.4.  Plasma aldosterone levels measurement 
To investigate the role of plasma aldosterone in diabetes, plasma aldosterone levels were 
measured in plasma samples using ELISA. There was a significant elevation in plasma 
aldosterone levels of 16 weeks db/db mice compared to age-matched lean controls (Figure 15, 
**p<0.001). 
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4.5.  Enzyme activities measurement  
To investigate the effect of hyperglycemia on renal ACE2 activity, kidney lysates and urine from 
db/db diabetic and lean control mice were analyzed using a fluorogenic substrate.  
a) Renal ACE2 activity: There was a significant increase in renal ACE2 activity of the 16 weeks 
old db/db mice compared to their age-matched lean control mice. (Figure 16, ***p<0.0001). 
b) Urinary ACE2 activity: 20µl of urine was used to determine the urinary ACE2 activity. There 
was also a significant elevation in the urinary ACE2 activity of 14 weeks old db/db mice 
compared to lean control mice (Figure 17, 
#
p<0.05). 
 
4.6.   Renal protein expression of ACE2, NEP and MR 
a) ACE2 protein expression: In 16 weeks db/db mice, renal ACE2 expression did not differ 
compared to lean control mice (Figure 33).  
b)  MR protein expression: There was a significant increase in renal MR expression of 16 weeks 
db/db diabetic mice compared to their age matched lean control mice (Figure 31, *p<0.05). 
c)   NEP protein expression: Renal NEP protein expression decreased significantly in the 16 
weeks db/db mice compared to lean control mice (Figure 31, *p<0.05). 
 
4.7.  Effect of rosiglitazone 
To evaluate the effect of normalizing hyperglycemia on type II diabetes related metabolic and 
renal parameters, juvenile (7 weeks) db/db mice were fed rosiglitazone (20mg/kg/day) mixed in 
standard diet for 10 weeks. 
a) Effect of rosiglitazone on blood glucose: Figure 1 showed that chronic treatment of db/db 
mice with rosiglitazone significantly decreased and normalized the blood glucose levels 
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compared to untreated db/db mice (*p<0.0001). This trend towards the normalization of blood 
glucose was seen immediately after 1 week treatment and was maintained constant throughout 
the treatment period. However, lean control mice treated with rosiglitazone did not show a 
difference in the blood glucose levels compared to untreated lean control mice (figure 1).  
In order to evaluate the effect of rosiglitazone on impaired glucose handling in db/db mice, a 
GTT was performed. Rosiglitazone demonstrated a significant improvement in the glucose 
utilization compared to untreated db/db mice (Figure 18, 
#
p<0.05). However, this effect was not 
seen in lean control mice treated with rosiglitazone (figure 18). 
b) Effect of rosiglitazone on urinary glucose excretion: Chronic treatment with rosiglitazone 
for 8 weeks demonstrated a significant decrease in the urinary glucose excretion of the treated 
db/db mice compared to untreated db/db mice (Figure 19, **p<0.001) 
c) Effect of rosiglitazone on body weights: Body weights increased consistently in 
rosiglitazone treated db/db mice compared to untreated db/db mice (Figure 2, *p<0.0001). Lean 
control mice treated with rosiglitazone did not show a difference in body weights compared to 
untreated lean controls (Figure 2). 
d) Effect of rosiglitazone on food intake: Despite a rise in plasma leptin levels of rosiglitazone 
treated db/db mice, food intake was not different in both treated and untreated db/db mice 
(Figure 3). Further, food intake did not vary in the rosiglitazone treated lean control mice (Figure 
3). 
e) Effect of rosiglitazone on water intake: In rosiglitazone treated db/db mice water intake 
decreased significantly compared to untreated db/db mice and fell to levels observed in lean 
control mice (Figure 4, *p<0.0001). Water intake of lean control mice treated with rosiglitazone 
remained the same as lean control mice (Figure 4).  
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f) Effect of rosiglitazone on absolute body fat: As expected rosiglitazone significantly 
augmented accumulation of absolute body fat in db/db mice compared to untreated db/db mice 
(Figure 5, *p<0.0001). This effect was not seen in rosiglitazone treated lean control mice 
compared to untreated lean control mice (Figure 5). 
g) Effect of rosiglitazone on absolute lean mass: There was a significant increase in absolute lean 
mass of the rosiglitazone treated db/db mice compared to untreated db/db mice (Figure 6, 
*p<0.0001).  
h) Effect of rosiglitazone on total body water: Total body water increased significantly in 
rosiglitazone treated db/db mice compared to untreated db/db mice (Figure 7, *p<0.0001). 
 
4.8.  Effect of rosiglitazone on plasma hormone parameters 
To examine the effect of normalization of hyperglycemia on type II diabetes related plasma 
hormonal and lipid changes, measurements were carried out using plasma from rosiglitazone 
treated db/db mice. 
a) Plasma insulin levels:  Chronic rosiglitazone treatment showed no effect on plasma insulin 
levels in 16 weeks treated db/db mice compared to untreated db/db mice (Table 3). 
b) Plasma leptin levels: Rosiglitazone significantly increased plasma levels of leptin and 
adiponectin in treated db/db mice compared to untreated db/db mice (Table 3, *p<0.05). 
c) Plasma adiponectin levels: Ten weeks of rosiglitazone treatment significantly increased the 
plasma adiponectin levels in treated db/db mice (9.1±1.5 µg/ml) compared to untreated  db/db 
(1.4±0.1 µg/ml) mice (Table 3, *p<0.05).  
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d) Plasma triglyceride levels: There was a significant reduction in plasma triglyceride levels of 
the rosiglitazone treated db/db mice compared to untreated db/db mice (Table 3, *p<0.05). In 
fact, rosiglitazone treatment normalized plasma triglyceride levels. 
e) Plasma glucagon levels: Plasma glucagon levels were significantly reduced in rosiglitazone 
treated db/db mice compared to untreated db/db mice (Table 3, *p<0.05). 
f) Plasma cholesterol levels: Normalization of hyperglycemia had no effect on plasma 
cholesterol levels in rosiglitazone treated db/db mice compared to untreated db/db mice (Table 
3). 
4.9.  Effect of rosiglitazone on renal function 
a) Urinary albumin: Chronic treatment with rosiglitazone for 8 weeks significantly 
ameliorated 24hr urinary albumin excretion in db/db mice (Figure 21, ***p<0.0001). This trend 
in urinary albumin reduction started after 4weeks of treatment and was maintained significantly 
low throughout the duration of study (Figure 21, ***p<0.001).  
b) Urinary total protein excretion: 24hr total protein excretion attenuated significantly in the 
treated db/db mice compared to untreated db/db mice (Figure 23, **p<0.001).  
 
4.10. Effect of rosiglitazone on plasma aldosterone levels 
Aldosterone levels did not differ in rosiglitazone treated db/db mice compared to untreated db/db 
mice (Figure 25). Similar effect was seen in lean control mice treated with rosiglitazone 
compared to untreated lean control mice (Figure 25). 
 
4.11. Effect of rosiglitazone on enzyme activities 
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a) Renal ACE2 activity: Renal ACE2 activity was also significantly reduced in rosiglitazone 
treated db/db mice compared to untreated db/db mice at 16 weeks age (Figure 27, **p<0.001). 
b) Urinary ACE2 activity: Chronic treatment with rosiglitazone for 8 weeks significantly 
reduced urinary ACE2 activity in rosiglitazone treated db/db mice compared to untreated db/db 
mice (Figure 29, **p<0.001). 
 
4.12. Effect of rosiglitazone on renal ACE2, NEP and MR protein expression 
a) Renal MR expression: There was a significant decrease in renal MR protein expression in 
rosiglitazone treated db/db diabetic mice compared to untreated db/db mice after 10 weeks of 
treatment (Figure 32, *p<0.05). 
b) Renal ACE2 expression: Renal ACE2 protein expression in rosiglitazone treated db/db 
diabetic mice was not different compared to untreated db/db mice after 10 weeks of treatment 
(Figure 33). 
c) Renal NEP expression: After 10 weeks of treatment renal NEP expression increased 
significantly in rosiglitazone treated db/db mice compared to untreated db/db mice (Figure 32, 
*p<0.05). 
 
4.13. Effect of spironolactone 
To evaluate effect of MR blockade on type II diabetes related metabolic and renal parameters, 
juvenile (7 weeks) db/db mice were fed spironolactone (100mg/kg/day) mixed in standard diet 
for 10 weeks 
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a) Effect of spironolactone on blood glucose: Chronic spironolactone treatment for 10 weeks 
did not affect the blood glucose levels of treated db/db mice compared to untreated db/db mice 
(Figure 8). 
b) Effect of spironolactone on urinary glucose excretion: Figure 20 showed that spironolactone 
treatment for 8 weeks significantly decreased the urinary glucose excretion in treated db/db mice 
compared to untreated db/db mice (*p<0.05). 
c) Effect of spironolactone on food and water intake: Treatment with spironolactone 
demonstrated a marked increase in food and water intake of the treated db/db mice compared to 
untreated db/db mice (Figures 10 and 11, *p<0.0001). 
d) Effect of spironolactone on body fat composition: There were no changes in the absolute 
body fat (Figure 12), absolute lean mass (Figure 13) and total body water (Figure 14) content in 
the spironolactone treated db/db mice compared to untreated db/db mice. 
 
4.14. Effect of spironolactone on plasma hormones 
a) Plasma insulin levels: Chronic treatment with spironolactone significantly decreased plasma 
insulin levels in 16 weeks old treated db/db mice compared to untreated db/db mice (Table 4, 
*p<0.05). 
b) Plasma triglyceride levels: Chronic treatment with spironolactone significantly decreased the 
plasma triglyceride levels in treated db/db mice compared to untreated db/db mice (Table 4, 
*p<0.05). 
c) Other plasma hormones: Spironolactone did not alter the plasma adiponectin, leptin, 
glucagon, and cholesterol levels of treated db/db mice compared to untreated db/db mice (Table 
4). 
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4.15. Effect of spironolactone on renal function 
a) Urinary albumin excretion: Urinary albumin excretion rate was not affected after 4 weeks and 
6 weeks of spironolactone treatment. However, treatment with spironolactone for 8 weeks 
demonstrated a significant reduction in the urinary albumin excretion of treated db/db mice 
compared to untreated db/db mice (Figure 22, ** p<0.01). 
b)  Total protein excretion: Chronic treatment with spironolactone for 8 weeks showed no 
difference in total protein excretion of treated db/db mice compared to untreated db/db mice 
(Figure 24). 
 
4.16. Effect of Spironolactone on plasma aldosterone levels 
There was a significant elevation in the plasma aldosterone levels in db/db mice treated with 
spironolactone compared to untreated db/db mice (Figure 26, 
#
p<0.05). Similar effect was 
observed in the lean control mice treated with spironolactone compared to untreated lean control 
mice (Figure 26, 
#
p<0.05). 
 
4.17. Effect of spironolactone on enzyme activities 
a) Renal ACE2 activity: There was a significant reduction in renal ACE2 activity in treated 
db/db mice compared to untreated db/db mice after 10 weeks of treatment (Figure 28, 
**P<0.001).  
b) Urinary ACE2 activity: No significant difference was seen in the urinary ACE2 activity of 
the treated db/db mice compared to untreated db/db mice after 8 weeks of treatment (Figure 30). 
 
4.18. Effect of Spironolactone on ACE2 and MR protein expression 
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Spironolactone treatment showed no difference in renal MR protein expression in the treated 
db/db mice compared to untreated db/db mice (Figure 34). Renal ACE2 protein expression 
decreased significantly in the spironolactone treated db/db mice compared to untreated db/db 
mice (Figure 34, *P<0.05). 
 
4.19. Immunohistochemistry of renal sections: Immunohistochemistry was performed to 
support the western blot results. Expression of NEP decreased in the cortex and medulla of 16 
week old db/db mice compared to lean controls (Figure 36). Treatment with rosiglitazone 
increased NEP protein expression in renal cortex as well as medulla (Figure 36). 
 
4.20. Western blot of urine: To detect the effect of rosiglitazone on changes in urinary 
excretion of ACE2, western blot was performed using 24hr urine samples from treated and 
untreated db/db mice and lean control mice.  
a) Immunoreactive band for ACE2 appeared at 90KDa in the 8 weeks old db/db and lean 
control mice (Figure 35).  
b) Results showed increased excretion of urinary ACE2 in untreated db/db mice compared to 
their age-matched lean control mice (Figure 35). 
c) After 2 weeks of treatment, rosiglitazone decreased the urinary ACE2 protein excretion in 
treated db/db mice compared to untreated db/db mice (Figure 35). 
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5. DISCUSSION 
In this emerging field of RAS there are only a few studies which address the role of 
hyperglycemia on renal ACE2. There is evidence that the deletion of the ACE2 gene leads to the 
development of Ang II dependent renal damage (Oudit et al., 2006). It is the ability of ACE2 to 
inactivate the vasoconstrictor, Ang II, and generate the putative reno and cardio protective 
metabolite, Ang (1-7), that implicates ACE2 as an important participant in cardiovascular 
homeostasis (Guy et al., 2003). 
In this study, we examined the benefits of rosiglitazone and spironolactone in the management of 
type II diabetes-induced renal dysfunction. In vivo studies were performed using db/db diabetic 
mice to determine the effect of hyperglycemia and aldosterone on renal ACE2 and albuminuria.  
Diabetic nephropathy is the leading cause of mortality which may eventually lead to end stage 
renal disease (Massi-Benedetti, 2002). The RAS is involved in the regulation of blood pressure 
and fluid volume (Ferrario, 2006). Ang II is formed from the Ang I via ACE and causes 
vasoconstriction, increase in aldosterone production, thirst and cardiac output (Morgan, 2003). 
Activation of RAS, especially Ang II and ACE, leads to hypertension, fluid retention and 
inflammation causing end organ damage in the long term (Brewster & Perazella, 2004; Cooper, 
2004). Ang II exerts several deleterious effects on the kidney and is considered crucial for the 
pathogenesis and progression of diabetic renal disease. It is responsible for the increase in 
intraglomerular capillary pressure and rearranges the podocyte skeleton and components of slit 
diaphragm all of which is responsible for glomerular sclerosis and increased urinary albumin 
excretion (Perico et al., 2008; Ruggenenti et al., 2010). ACEIs and ARBs are efficient in 
inducing renoprotection in diabetes by suppression of Ang II activity and production (Tan et al., 
2010). However, in some patients chronic treatment with ACEIs and ARBs was not completely 
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effective in causing renoprotection due to a phenomenon called “aldosterone escape” or 
“breakthrough phenomenon” (Schjoedt et al., 2004). 
There is a positive correlation between plasma aldosterone and plasma glucose levels in the 
diabetic rat models (Han et al., 2006). The results of the present study demonstrate that plasma 
aldosterone levels are increased in db/db diabetic mice compared to non diabetic lean controls. 
This finding agrees with the previous study where the plasma aldosterone levels were 
significantly elevated in the zucker diabetic fatty rats (Fredersdorf et al., 2009). This is also 
supported by a clinical study which showed that plasma aldosterone levels were elevated in 
subjects with metabolic syndrome (Bochud et al., 2006).  
There is evidence that hyperglycemia activates the RAAS and increases tissue and circulating 
levels of Ang II and aldosterone (Xue & Siragy, 2005; Zhao et al., 2006b). Aldosterone mediates 
renal and cardiovascular injury via activation of MR. Hence we proposed that MR blocker 
spironolactone and/or insulin sensitizer rosiglitazone decreases the elevated plasma aldosterone 
levels in the db/db mice. However, our data showed that chronic treatment with rosiglitazone 
normalized the hyperglycemia in db/db mice without altering plasma aldosterone levels.   
Increasing evidence suggests that abdominal fat and other fat derived factors such as 
adipocytokines stimulate the secretion of aldosterone in obese subjects (Kidambi et al., 2007). 
We also found that rosiglitazone treatment increased the absolute body fat in the db/db mice 
compared to the untreated db/db mice. This finding suggests the possible involvement of 
alternative stimuli such as, the amount of fat tissue, in increasing plasma aldosterone levels apart 
from uncontrolled glycemia. Treatment with eplerenone increased plasma aldosterone levels in 
both type I and type II diabetic mice (Guo et al., 2006). Eplerenone also elevated the plasma 
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aldosterone concentration in Dahl salt-sensitive hypertensive rats fed a low sodium diet (Takeda 
et al., 2007). In agreement with the above studies, our results demonstrated a significant increase 
in plasma aldosterone levels of the db/db mice treated with spironolactone (100mg/kg body wt) 
compared to the untreated db/db mice. 
Consistent with many findings we found that the MR blocker, spironolactone, had no effect on 
the blood glucose and glucose tolerance of the db/db mice although initial few weeks 
demonstrated a decrease in the blood glucose levels. In contrast, eplerenone treatment improved 
glucose tolerance and reduced plasma glucose levels of ob/ob and db/db mice (Hirata et al., 
2009). The reason for this difference could be attributable to the fact that we treated the mice for 
a longer duration of 10 weeks whereas Hirata et al., 2009 treated them for only 3 weeks.  
Plasma aldosterone levels are positively correlated with plasma triglycerides in subjects with 
high aldosterone levels (Goodfriend et al., 1995; Krug & Ehrhart-Bornstein, 2008). We found 
that spironolactone treatment showed no apparent changes in the plasma adiponectin levels of 
the db/db mice but decreased the plasma triglyceride levels. This data was supported by a study 
done on high-fat, high-fructose fed C57BL/6 mice where treatment with an MR antagonist 
spironolactone significantly reduced triglyceride levels (Wada et al., 2010). However, our results 
showed no changes in the plasma cholesterol, leptin and glucagon levels of the db/db mice 
treated with spironolactone compared to untreated db/db mice. 
Microalbuminuria is an early clinical sign of renal dysfunction and a predictor of diabetic 
nephropathy in patients with diabetes (Gall et al., 1997). In agreement with our previous 
findings, we showed that db/db mice depicted microalbuminuria and hyperglycemia at an early 
age of 5 weeks. In addition, our previous studies showed that blood pressure begins to rise at 12 
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weeks age (Senador et al., 2009). Thus, we concluded that early stages of kidney damage are 
caused by hyperglycemia but not hypertension. As the age progresses, disease progresses and 
kidney function declines further, resulting in a significant increase in albuminuria at 14 weeks 
compared to 5 weeks. Data from the largest clinical study till date, United kingdom prospective 
diabetes study (UKPDS), showed that microvascular complications of diabetes such as 
retinopathy and nephropathy can be decreased by implementing strict glycemic control (UKPDS, 
1998). Further, intense blood pressure control with RAS inhibitors also aid in reduction of 
microalbuminuria (Parving et al., 2001). 
 Considerable research has been done over the past 10 years suggesting the role of aldosterone in 
renal injury and causing tissue fibrosis and inflammation. Several animal and clinical studies 
demonstrated the beneficial effects of inhibition of aldosterone system on diabetic nephropathy 
(Nishiyama & Abe, 2006; Del et al., 2007; Han et al., 2006; van den Meiracker et al., 2006). 
Moreover, treatment with spironolactone improved renal function in several animal models of 
renal injury (Trachtman et al., 2004; Feria et al., 2003; Blasi et al., 2003).  
(Guo et al., 2006) reported that, 25wk old db/db mice treated with eplerenone for 17 weeks 
showed a marked attenuation in albuminuria compared to untreated db/db mice. In agreement 
with this study, we showed that treatment with spironolactone for 8 weeks demonstrated a 
marked attenuation in the urinary albumin excretion rate. Interestingly, spironolactone treatment 
did not show a significant decrease in the albuminuria after 4 weeks and 6 weeks treatment. 
Moreover db/db mice became hypertensive after 11 weeks. Thus, it is likely that the observed 
effects were related to the influence of hypertension. Although many animal studies 
demonstrated blood pressure independent renoprotective effects of MR, it is still unclear whether 
the observed effect is related to the blood pressure or not (Kiyomoto et al., 2008; Nishiyama et 
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al., 2009). Low doses of spironolactone in combination with other antihypertensive medications 
like ACEIs or ARBs lowers blood pressure as well as albuminuria (Schjoedt et al., 2006). Most 
of the clinical and animal studies reported the beneficial effects of MR blockers either in 
combination with ACEIs or ARBs or both. Dual blockade of Ang II and aldosterone using ARBs 
and MR blockers could be more effective in preventing the progression of proteinuria in type 2 
diabetic rats (Nishiyama et al., 2010b). This could be one reason to explain why there is a 
delayed renoprotective effect with spironolactone in our study. Incomplete blockade of RAS 
results in augmentation of AT1R mediated Ang II actions. Hence BP, inflammation and ROS 
production increases. 
The PPARγ agonist rosiglitazone has been suggested to exert cardiovascular and renal protection 
through the improvement of lipid metabolism, anti-inflammation, anti-proliferation. However, 
whether RAS is involved in the renoprotective effects of PPARγ agonists is not fully elucidated. 
One of the goals of the present study aimed to investigate the effects of the RAS on the 
renoprotection mediated by PPARγ agonists. For this db/db mice were fed with rosiglitazone 
(20mg/kg/day) in standard chow for duration of 10 weeks. Rosiglitazone belongs to the class of 
thiazolidinediones (TZDs) which is used to treat type II diabetes by improving insulin sensitivity. 
Renoprotective properties of TZDs have been studied extensively over the past many years. In 
the present study we observed a significant fall in the urinary albumin excretion (UAE) and 
protein excretion of the db/db mice 4 weeks after the commencement of the treatment. Moreover, 
there is a significant decline in blood glucose levels of the db/db mice to normal levels 
immediately after 1 week. This finding clearly demonstrates the significance of strict glycemic 
control in preventing diabetic renal injury. 
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Rosiglitazone depicted beneficial effect on urinary albumin and protein excretion on several 
mouse models of obesity and type II diabetes (Buckingham et al., 1998; Khan et al., 2005). It is 
noteworthy that rosiglitazone offers superior renal protection over ACEIs in a rat model of type 
II diabetes with obesity (Baylis et al., 2003). In addition, rosiglitazone decreased UAE by 35% 
after 26 weeks of treatment in patients with type II diabetes and hypertension (Sarafidis et al., 
2005), whereas in a separate study involving type II diabetes and microalbuminuria patients, 
rosiglitazone decreased the UAE by 60% after 12 weeks of treatment (Pistrosch et al., 2005). 
Although the first study emphasized the positive correlation between BP changes and changes in 
UAE, the later found no correlation between changes of UAE and BP. In non-diabetic 
hypertensive patients, rosiglitazone is known to reduce systolic and diastolic BP thereby 
providing cardiovascular benefits (Raji et al., 2003). It is well documented that hyperglycemia 
and insulin resistance contribute to the development of oxidative stress and production of free 
radicals (Ceriello, 2000). TZDs contribute to attenuation in oxidative stress by reversing 
hyperglycemia and insulin resistance (Noguchi et al., 1996).  Although most of these parameters 
were not measured in our study, it is tempting to speculate that reduction in blood glucose levels, 
BP, anti-inflammatory and anti-oxidative properties contribute to the overall improvement of 
UAE and renal function in the db/db mice. 
Western blot analysis revealed that renal ACE2 expression increased in16 weeks old db/db mice. 
This leads to increased formation of Ang (1-7) in the kidneys which mediates actions opposite to 
Ang II. High ACE and low ACE2 protein expression in the glomerulus of the db/db mice 
resulted in increased Ang II production and decreased Ang II degradation (Ye et al., 2006). 
Imbalance in ACE/ACE2 resulted in an increase in the intraglomerular pressure. Moreover, Ang 
II dependent blood pressure increased substantially in ACE2 - deficient mice than in wild type 
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mice (Gurley et al., 2006). In addition, our results demonstrated an increase in the renal MR 
protein expression of db/db mice. In agreement with (Guo et al., 2006), we demonstrated 
increased renal MR expression in db/db diabetic mice which could contribute to increased MR 
activity and further augments the BP and renal damage. Thus, renal ACE2 is upregulated in 
order to oppose the deleterious effects of hypertension as well as hyperglycemia induced 
intraglomerular pressure in the kidney of db/db mice. 
Several animal studies investigated the beneficial effect of MR blockade on tissue RAS. One of 
the goals of the present study is to see whether MR blocker, spironolactone, reduces the 
albuminuria by upregulating ACE2. Our results demonstrated that, treatment with the MR 
blocker, spironolactone downregulated the expression of ACE2 in the kidney of db/db mice 
compared to untreated db/db mice. In contrary, (Takeda et al., 2007) showed that MR blockade 
with eplerenone reduced the mRNA expression of ACE in the heart of Dahl-salt sensitive 
hypertensive rats but did not alter the ACE2 mRNA expression. However, ACE2 mRNA 
expression was increased when eplerenone was used in combination with an AT1 receptor 
blocker. In another study, it was reported that eplerenone treatment decreased AT1 mRNA 
expression as well as angiotensinogen in the kidney of Dahl-salt sensitive rats (Zhu et al., 2009). 
These findings suggest the importance of local RAS in the pathophysiology of cardiac and renal 
dysfunction. However, there are few studies which examined the renoprotective effects of MR 
blockade on the kidney of db/db mice. Several lines of experimental studies conducted on stroke-
prone spontaneously hypertensive rats reported that anti-proteinuric effects seen with MR 
antagonists are independent of RAS blockade. In addition, we also found that spironolactone has 
no effect on the MR expression in the kidney of db/db mice. Based on this we speculate that the 
reduction in urinary albumin excretion observed in db/db mice may be independent of ACE2. 
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Moreover, treatment with rosiglitazone did not alter renal ACE2 expression in db/db mice. 
Further, renal NEP expression increased significantly in the rosiglitazone treated db/db mice. 
Increase in NEP protein expression suggests the possible involvement of alternative pathways in 
Ang 1-7 production. This could also be a plausible explanation for unaltered renal ACE2 
expression in the rosiglitazone treated db/db mice. Although plasma aldosterone levels are not 
decreased, there is a significant decrease in the MR protein expression in the kidney of db/db 
mice treated with rosiglitazone. Increase in NEP coupled with a decrease in MR protein 
expression shows that intra renal RAS plays a crucial role in renal tissue injury in diabetes. A 
study reported that rosiglitazone normalized gene expression of ACE in the kidney of obese 
zucker rats (Song et al., 2008). Several in vitro studies were also performed to demonstrate the 
influence of rosiglitazone on RAS. It has been shown that rosiglitazone downregulates the 
expression of AT1R but up-regulates the AT2R protein expression in the vascular smooth 
muscle cells (Ren et al., 2011). Other studies reported that rosiglitazone attenuates the production 
of Ang I and II from human subcutaneous adipocytes (Harte et al., 2005). Our results coupled 
with these findings allow speculations that the renoprotective effects of rosiglitazone could be 
partly mediated by its influence on RAS. However, a study conducted on normoalbuminuric type 
II diabetes patients reported that RAS is not the main mechanism through which TZDs reduce 
diabetic nephropathy. This concludes that apart from ACE2, other Ang (1-7) forming enzymes, 
such as NEP, play a crucial role in mediating renoprotective effects in db/db diabetic mice. 
To confirm whether a decrease or increase in ACE2 expression is directly associated with a 
decrease or increase in ACE2 activity we performed renal ACE2 activity. In agreement with the 
western results, renal ACE2 activity increased in16 weeks old db/db mice compared to lean 
controls. Our previous studies reported that ACE2 activity increased but ACE activity decreased 
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in the kidney of 8 weeks db/db mice. This combination suggests the beneficial effects of ACE2 
in protecting the kidney against Ang II induced damage. Several lines of animal studies depicted 
the detrimental effects of knocking out ACE2 or pharmacologically inhibiting ACE2 on renal 
dysfunction in diabetes. This notion is supported by a study conducted in STZ mice where 
chronic pharmacological inhibition of ACE2 by MLN-4760 worsened albuminuria and 
glomerular mesangial matrix expansion (Soler et al., 2007). They also postulated that the ACE2 
inhibition is associated with enhanced ACE expression in the glomerulus and Ang II formation. 
Further, 4 weeks after treatment with MLN-4760, ACE2 activity decreased in STZ mice. 
Another study depicted an attenuation in the renal cortical ACE2 activity in a mouse model of 
CKD (5/6 nephrectomy or 5/6 Nx mice) treated with MLN-4760 for 4 weeks (Dilauro et al., 
2010).  
Treatment with spironolactone, showed attenuation in renal ACE2 activity in the db/db mice 
compared to untreated db/db mice. In contrary, human monocyte-derived macrophages obtained 
from congestive heart failure patients treated with spironolactone (25mg/day) for 1 month 
demonstrated an increase in ACE2 activity (Keidar et al., 2005). Moreover, in the same study 
treatment of Balb/C mice (model for cardiovascular, cancer and immunology research) with 
eplerenone (200mg/kg/day) for 2 weeks demonstrated an increase in cardiac ACE2 activity but 
not renal ACE2 activity. This clearly demonstrates that ACE2 plays a vital role in the 
cardioprotective effects exhibited by an aldosterone blocker. As illustrated in many clinical and 
animal studies, MR blockade in combination with ACEIs or ARBs might be more effective in 
modulating beneficial effects in the kidney. However, due to the limited number of studies 
available on db/db mice, further investigation is required to clarify the monotherapy of MR 
blockade on kidney dysfunction and RAS.  
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As mentioned before we found an increase in renal ACE2 protein expression as well as ACE2 
activity in the db/db mice. This finding was supported by various diabetic animal model studies 
(db/db and Akita) which showed that there is an early increase in the renal ACE2 expression and 
activity (Wysocki et al., 2006; Wong et al., 2007). We also postulated that this could be a 
possible mechanism through which the kidney protects itself from initial stages of kidney 
damage induced by hyperglycemia. However in the long run, renal ACE2 expression decreases 
in the diabetic rat models (Tikellis et al., 2003). (Oudit et al., 2010) reported that, human 
recombinant ACE2 decreased urinary albumin excretion independent of hyperglycemia but with 
a mild blood pressure lowering effect in Akita mice. Accordingly, we evaluated the effect of 
reduction of hyperglycemia on renal ACE2 activity. However, our western results indicate that, 
renal ACE2 activity decreased in the db/db mice treated with rosiglitazone. In the absence of a 
blood glucose lowering agents intra renal ACE2 plays a vital role in protecting the kidney 
against damage caused by inappropriate activation of RAS, especially Ang II. This decrease in 
ACE2 activity in the kidney could be due to the fact that mechanisms other than intra renal RAS 
involved in the pathogenesis of kidney damage are inhibited by rosiglitazone. Hence, there is no 
need for upregulation of renal ACE2.  
Advancement in the field of urinary biomarkers and their role in predicting the changes in kidney 
led to our assumption that urinary ACE2 could be a biomarker of intra renal RAS status. Our 
results demonstrated an increase in the urinary ACE2 expression in the 8 weeks db/db mice. 
(Wang et al., 2008) showed that, there is a strong correlation between urinary mRNA expression 
of ACE2 and degree of proteinuria. Therein we showed that urinary albumin excretion increased 
in young db/db mice compared to controls. Further, we found that at 14 weeks ACE2 activity 
increased in db/db mice. This data suggest that the increase in urinary ACE2 expression is 
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related to the increase in albuminuria. During early stages of kidney damage ACE2 increases and 
as a result more ACE2 is excreted into the urine. However, treatment with rosiglitazone 
decreased the urinary ACE2 activity significantly indicating that there is an improvement in the 
tubular function of the kidney. Moreover, rosiglitazone also decreased urinary ACE2 protein 
output in 8 week db/db mice compared to controls. We speculate that decreased urinary ACE2 
expression correlates with a decreased renal ACE2 expression in db/db mice treated with 
rosiglitazone. Thus, urinary ACE2 could be used as an early biomarker for the detection of intra 
renal RAS status and kidney damage in diabetes. 
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6. CONCLUSION 
The RAS pays a pivotal role in the development and progression of diabetic nephropathy. 
Hyperglycemia activates RAS and increases tissue and circulating levels of Ang II and 
aldosterone. Elevated Ang II and aldosterone contribute to the development of albuminuria. A 
new player in RAS is ACE2, which has been shown to be renoprotective in early stages of 
diabetes. Several lines of evidence showed that pharmacological inhibition or deletion of ACE2 
worsened albuminuria and glomerular sclerosis in diabetes. Microalbuminuria is an early clinical 
sign of renal dysfunction and a predictor of diabetic nephropathy in patients with diabetes. In the 
present study we showed that diabetic db/db mice developed hyperglycemia and 
microalbuminuria at a very young age. With age, disease progressed and renal function declined 
further leading to a further elevation in the albumin excretion. In addition, plasma aldosterone 
levels were elevated in the db/db mice. Thus, we speculate that elevated plasma aldosterone 
levels contribute to the development of albuminuria. The aim of the present study is to show that 
renoprotection offered by anti-diabetic medication rosiglitazone and MR antagonist 
spironolactone is mediated via ACE2.  
 Chronic rosiglitazone treatment (20mg/kg/day) normalized the blood glucose levels and 
markedly attenuated the urinary albumin excretion and total protein excretion in db/db mice 
compared to untreated db/db mice. In addition, chronic spironolactone treatment (100mg/kg/day) 
showed no effect on blood glucose levels but reduced the urinary albumin excretion in db/db 
mice. Both rosiglitazone and spironolactone significantly decreased renal ACE2 expression and 
activity in treated db/db mice. In addition, rosiglitazone also decreased urinary ACE2 expression 
as well as activity. This indicates that rosiglitazone offers renoprotection by preventing the 
shedding of ACE2 from the kidney. However, spironolactone showed no effect on the urinary 
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ACE2 activity. Further, rosiglitazone significantly attenuated MR expression whereas 
spironolactone showed no effect on MR protein expression. Interestingly, rosiglitazone increased 
renal NEP protein expression in db/db mice. These results were also confirmed by 
immunohistochemistry which demonstrated increased staining for NEP in the kidney of 
rosiglitazone treated db/db mice. Thus, renoprotection induced by rosiglitazone or spironolactone 
may not be mediated via ACE2. However, up regulation of NEP coupled with decrease in 
albumin excretion suggests the involvement of other Ang (1-7) forming enzymes apart from 
ACE2 in offering renoprotection mediated by rosiglitazone. 
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APPENDIX A  
 
Endogenous Expression of the Renin Angiotensin System In Cos7 Cells  
 
Leite AP, Chodavarapu H, Weir NM, Quan R, Difulvio M, Fiorino P, Elased KM.  
 
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
The renin angiotensin system (RAS) plays a vital role in regulating physiological processes of 
the cardiovascular system such as blood flow, sodium, bicarbonate and water transport, cell 
growth and differentiation. Alterations in RAS are considered crucial for the development of 
diabetic complications like renovascular hypertension and nephropathy. Angiotensin II is the 
primary effector of RAS. Angiotensin converting enzyme (ACE) produces the vasoconstrictor 
angiotensin II from angiotensin I, while angiotensin converting enzyme 2 (ACE2) cleaves 
angiotensin II to form the vasodilator angiotensin 1-7. Angiotensin II acts through two major G-
protein coupled receptor subtypes: angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2). 
The AT1 receptor is most notably responsible for vasoconstriction, renal tubule sodium re-
absorption, cellular differentiation, and increased aldosterone secretion. All of these directly 
contribute to the progression of chronic kidney disease, including diabetic nephropathy. 
Traditional animal models used to study renal RAS lack the genetic plasticity and rapid 
throughput possible in cell culture. The COS7 is a robust and easily transfectable cell line 
derived from the kidney of the African green monkey, Cercopithecus aethiops. However, 
previous reports indicate COS7 cells normally lack angiotensin II type1receptor. Therefore, the 
aim of this study was to show the expression of the RAS components such as AT1, ACE, and 
ACE2 in COS7 cells. Untreated cells were grown to 90% confluency, homogenized in lysis 
buffer and protein was separated on 10% SDS polyacrylamide gel electrophoresis. Proteins were 
transferred onto a PVDF membrane and probed for components of RAS using anti-AT1, anti-
ACE and anti-ACE2 antibodies. In COS7, we clearly detected AT1 (43 kDa), ACE (195 kDa) 
and ACE2 (90kDa). This is the first time endogenous components of RAS have been 
documented in COS7 cells. In conclusion, the COS7 mammalian kidney cells express several 
components of the RAS. The hardy and transfectable nature of this cell line makes it an attractive 
in vitro model for manipulating components of the renal renin angiotensin system. 
 
Poster presented in XXV Annual Meeting of Federation of Societies of Experimental Biology 
(FESBE); Brazil. 2010 
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APPENDIX B 
 
Expression of Renin Angiotensin System in The Kidney Fibroblast Cell Line COS-7 
 
Mauricio Di Fulvio, Harshita Chodavarapu & Khalid M. Elased 
 
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
The renin angiotensin system (RAS) plays a vital role in regulating the cardiovascular and renal 
system. Recent discovery of angiotensin converting enzyme 2 (ACE2) provides a new site for 
therapeutic intervention of hypertension and renal diseases. Angiotensin converting enzyme 
(ACE) produces the vasoconstrictor angiotensin II from angiotensin I, while angiotensin 
converting enzyme 2 (ACE2) cleaves angiotensin II to form the vasodilator angiotensin 1-7. 
There is a need for a rapid throughput assay in transfectable cell cultures to study the cross-talk 
between different arms of the RAS. In addition it is difficult to dissect a direct effect of anti- 
hypertensive agents on renal RAS in vivo. COS7 is a robust and easily transfectable cell line 
derived from the kidney of the African green monkey, Cercopithecus aethiops. Previous reports 
indicated that COS7 cells lack angiotensin II receptor 1 (AT1R). The aim of this study was to 
investigate whether the kidney fibroblast cell line COS7 endogenously express the components 
of the RAS. In addition we investigated the presence of ACE and ACE2 enzymatic activities in 
these cells. COS7 were grown to 90% confluency, homogenized in lysis buffer containing 
protease inhibitors. Western blot and immunohistochemistry were used to determine RAS’ 
component at the protein level. ACE and ACE2 activities were measured using ³H-hippuryl 
glycyl-glycine and Mca-APK [Dnp] substrates, respectively. RT-PCR and gene-specific sets of 
primers were used to amplify ACE, ACE2, AT1R, AT2R and Renin transcripts expressed in 
COS7. In this cell line, we clearly detected immunoreactive bands for AT1R (43 kDa), ACE 
(195 kDa), ACE2 (90 kDa) and Renin (41 kDa). Our immunohistochemistry results also show 
the presence of ACE, ACE2 and Renin proteins in COS7. There is evidence of ACE2 activity in 
COS7 (1-20 mg protein). Interestingly, COS7’s lysates acted synergistically with mouse kidney 
lysates and significantly enhanced ACE2 activity (3-5 fold increase, p>0.0001). This ACE2 
activity was blocked with the specific ACE2 inhibitor MLN 4647. In conclusion, this is the first 
study to demonstrate endogenous expression of the RAS in COS7 cells. Transfectable nature of 
this cell line makes it an attractive in vitro model for manipulating components of the renal RAS. 
 
Poster presented at the American Heart Association High Blood Pressure Research 2010, 
Washington, D.C. 
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APPENDIX C 
 
Functional And Molecular Evidence For The Expression of Renin Angiotensin System In 
COS-7 Cells  
 
Harshita Chodavarapu, Khalid M. Elased & Mauricio Di Fulvio 
 
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
The renin angiotensin system (RAS) is a major regulator of renal and cardiovascular functions. 
There is a need for a rapid throughput assay in transfectable cell culture to study the cross talk 
between different arms of RAS. COS-7 is an easily transfectable cell line derived from the 
kidney of the African green monkey, Cercopethicus aethiops. Previous studies indicated that 
COS-7 cells lack angiotensin II type I receptor (AT1R). The aim of this study was to investigate 
whether COS-7 cells endogenously express RAS components. Cells were grown to 90% 
confluency and homogenized in lysis buffer containing protease inhibitors. Western blot and 
immunohistochemistry were performed to examine the RAS protein expression. ACE and ACE2 
activities were measured. RT-PCR and specific sets of primer sets were used to amplify ACE, 
ACE2, AT1 and RENIN transcripts. Western blot analysis demonstrated expression of AT1 
(43KDa), ACE (195KDa), ACE2 (90KDa) and renin (41KDa) at the protein level. Further 
immunohistochemistry experiments demonstrated expression of ACE, ACE2, AT1, renin and 
Mas (Ang1-7 receptor) in COS-7. At the functional level, ACE and ACE2 activities in COS-7 
lysate were selectively inhibited by lisinopril and MLN-4760 respectively. 
Conclusion: This is the first report to demonstrate functional endogenous expression of the RAS 
in COS-7 cells. 
 
 
Poster presented at the Experimental Biology (EB) meeting 2011; Washington D.C. 
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APPENDIX D 
 
Decreased aortic angiotensin converting enzyme (ACE2) and phospho-eNOS protein 
expression in db/db diabetic mice. 
 
Narges Kablan, Harshita Chodavarapu, Rendong Quan, Mauricio DiFulvio, Khalid M Elased 
 
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Cardiovascular disease is a long term complication of diabetes and remains a leading cause of 
morbidity and mortality. ACE2 is a homologue of ACE that preferentially converts the 
vasopressor angiotensin II (Ang II) to the vasodilator Ang (1-7). Endothelial nitric oxide 
synthase (eNOS) produces the endogenous vasodilator nitric oxide (NO). There is evidence that 
diabetes impairs ACE2 and NO-mediated vasodilation. Our previous studies demonstrated an 
age-dependent increase of blood pressure in db/db type 2 diabetic mice as well as a decrease and 
increase in renal ACE and ACE2 protein expression respectively in 8 wks db/db mice. The goal 
of this study was to investigate the role of ACE2 and phospho-eNOS in the pathogenesis of 
hypertension in db/db diabetic mice. Plasma and tissue ACE and ACE2 activities were 
measured. Western blot demonstrated a significant decrease in aortal ACE2 and phospho-eNOS 
protein expression in 12 wk hypertensive db/db mice compared to controls (p<0.001). However, 
aortal renin, ACE, neprilysin and total eNOS protein expression were not altered in db/db mice. 
There was a significant increase in plasma ACE activity in db/db mice. In conclusion, down 
regulation of aortal ACE2 and phospho-eNOS protein expression coupled with increased plasma 
ACE activity may contribute to the evolution of hypertension in db/db diabetic mice. 
 
 
Poster presented at the Experimental Biology (EB) meeting 2011; Washington D.C. 
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APPENDIX E 
 
Decreased aortic angiotensin converting enzyme 2(ACE2) and neprilysin (NEP) protein 
expression in db/db diabetic mice  
 
Harshita Chodavarapu, Narges Kablan, Rendong Quan, Khalid M Elased    
                                    
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Cardiovascular disease is a long term complication of diabetes and is associated with dysfunction 
in the renin angiotensin system (RAS).  Emerging evidence shows that the vasoconstrictor 
actions of Angiotensin II may be opposed by formation of the vasodilator, Ang (1-7). ACE2 
coverts Ang II to the vasodilator, Ang (1-7). Neutral endopeptidase (NEP), a cell surface 
metallopeptidase also generates Ang (1-7) by degrading angiotensin I. Ang (1-7) mediates its 
vasodilatation action through a G protein-coupled receptor (Mas). In our previous studies we 
demonstrated an age-dependent increase of blood pressure in db/db type 2 diabetic mice. The 
goal of this study was to evaluate whether there is an age-dependent changes in aortic ACE, 
ACE2 and NEP protein expression in db/db diabetic mice. Plasma ACE and ACE2 activities 
were measured. Western blot analysis demonstrated a significant decrease in aortal ACE2 and 
NEP protein expression in 12 wk hypertensive db/db mice compared to controls (p<0.001). 
There was also a significant decrease in the kidney NEP protein expression in the 16 week db/db 
mice compared to lean control mice. In addition there was no difference in Mas receptor protein 
expression in the kidney of 12 wk db/db mice compared to control. There was a significant 
increase in plasma ACE activity in db/db mice. In conclusion, alteration in the balance between 
Ang II and Ang (1-7) forming enzymes (ACE2 and NEP) could contribute to the development of 
hypertension in db/db diabetic mice.                                                                                                                                                                           
 
 
Poster presented at the American Diabetes Association's 71st Scientific Sessions, San Diego, 
CA. 2011. 
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APPENDIX F 
 
Rosiglitazone Increases Renal Neprilysin Protein Expression And Decreases Albuminuria 
In db/db Diabetic Mice 
 
Harshita Chodavarapu, Esam Salem, Narges Kablan, Khalid M. Elased 
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Alterations within the renin angiotensin system (RAS) are pivotal for the development and 
progression of cardiovascular and renal disease. Diabetic nephropathy (DN) is one of the 
microvascular complications of diabetes and a major cause of morbidity and mortality. Clinical 
hallmarks of DN include a progressive increase in urinary albumin excretion and a decline in 
glomerular filtration rate, which occur in association with an increase in blood pressure, 
ultimately leading to end-stage renal failure. Studies have shown that the strict glycemic control 
and blockade of renin angiotensin system attenuates diabetic kidney damage. Angiotensin II 
(Ang II), a potent vasoconstrictor cleaved from Ang I, is responsible for the renal damage in 
diabetes. Neutral endopeptidase (NEP), a metallopeptidase forms Ang (1-7) by degrading 
angiotensin I. The precise mechanism(s) via which thiazolidinediones (TZDs) such as 
rosiglitazone reduce albuminuria is yet to be defined. The aim of this study is to test the 
hypothesis that the renoprotective effects of PPARγ agonist, rosiglitazone in db/db mice is at 
least partially mediated by upregulation of NEP. Male 6 week db/db mice were fed rosiglitazone 
(10 mg/kg for 8 weeks). Significant decrease in blood glucose levels was observed in the db/db 
mice treated with rosiglitazone (158.8±27.68 mg/dL) compared to untreated db/db mice 
(795.1±16.92 mg/dL). Rosiglitazone improved glucose tolerance in db/db mice. In addition, 
rosiglitazone treated db/db mice depicted an increase in plasma adiponectin levels in db/db mice 
(treated: 9129±1426; untreated: 1416±119.9 pg/mL). Treatment with rosiglitazone significantly 
decreased urinary albumin excretion in db/db mice (untreated: 455.6±66.52; treated: 
270.9±16.34 µg albumin /mg creatinine). Western blot analysis demonstrated a significant 
increase in renal NEP protein expression in 16wk db/db mice treated with rosiglitazone 
compared to control db/db mice (p<0.05). In summary, normalizing blood glucose levels with 
TZDs would impart renal protection in db/db diabetic mice by increasing renal NEP protein 
expression.                                                                                                                                                                          
                                                                                                                                      
Poster will be presented at the American Heart Association High Blood Pressure Research 
2011, Orlando, FL. 
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